查看購物車
  • English
  • Japanese
  • Korean
生殖健康基因篩檢和檢測市場—全球及區域分析：按產品、檢測類型、遺傳疾病、技術方法、檢體類型、最終用戶和地區分類—分析與預測（2026-2036 年）
市場調查報告書
商品編碼
2132668

生殖健康基因篩檢和檢測市場—全球及區域分析：按產品、檢測類型、遺傳疾病、技術方法、檢體類型、最終用戶和地區分類—分析與預測（2026-2036 年）

Genetic Screening and Testing for Reproductive Health Market - A Global and Regional Analysis: Focus on Offering, Test Type, Genetic Disorder, Technology Approach, Sample Type, End User, and Region - Analysis and Forecast, 2026-2036
出版日期: | 出版商: BIS Research | 英文 296 Pages | 商品交期: 1-5個工作天內

價格

全球生殖健康基因篩檢和檢測市場預計到 2025 年將達到 90.126 億美元，到 2036 年將達到 247.097 億美元，2026 年至 2036 年的複合年成長率為 9.73%。

關鍵市場統計數據
預測期 2026-2036
2026 年市場規模 97.665億美元
2036年的預測 247.97億美元
複合年成長率 9.73%

該市場涵蓋用於識別染色體異常、遺傳疾病和其他影響不孕症、胚胎活力、懷孕結果或遺傳風險的基因組因素的產品、軟體和檢測服務。該市場支持孕前計畫、基於適應性因素的不孕症評估、輔助生殖技術、胚胎檢測、產前篩檢、確診產前診斷和流產調查。主要檢測類別包括帶因者篩檢、不孕症基因檢測、胚胎著床前遺傳學檢測 (PGT)、非侵入性產前檢測 (NIPT) 和其他生殖遺傳學檢測。

由於產前常規應用無細胞DNA篩檢、體外受精（IVF）和胚胎檢測數量的增加、祖源攜帶者篩檢策略的推廣、定序技術的進步以及生物資訊學和結果解讀的自動化，非侵入性產前檢測（NIPT）的需求正在不斷成長。 NIPT是一種使用母體血液進行的篩檢測試，如果結果呈陽性或高風險，則可能需要諮詢和確診程序。然而，市場成長取決於保險報銷、患者的經濟承受能力、臨床效用的證據、專家諮詢的可及性、檢查室品質、監管要求以及倫理認可度。

市場概覽

全球生殖健康基因篩檢和檢測市場包括市售產品和檢查室服務，這些產品和服務用於識別與受孕、生育力、胚胎髮育、懷孕和遺傳風險相關的遺傳因素。本研究涵蓋的檢測包括靶向和擴展的攜帶者篩檢、基於適應症的不孕症基因檢測、用於檢測非整倍體、結構重排、單基因疾病和多基因疾病的胚胎植入前遺傳學檢測 (PGT)、無創產前檢測 (胚胎著床前)、有創產前檢測、受精卵檢測以及復發性流產的基因評估。

此產品模式結合了產品和服務。產品包括基於NGS（次世代定序）、微陣列及其他耗材和試劑；定序、微陣列和細胞遺傳學分析儀器；以及用於品管、變異分析、工作流程管理、結果解讀和報告的軟體和生物資訊工具。服務包括檢體處理、定序或細胞遺傳學分析、生物資訊學、突變解讀、臨床報告和實驗室支援。因此，除了對分析平台的選擇性資本投資外，還需要持續投入檢查室服務和耗材費用。

根據生殖過程的不同，檢測技術和檢體的選擇也各不相同。血液、唾液和口腔拭子用於基因帶原檢測和不孕症檢測。透過切片檢查採集的胚胎細胞用於胚胎植入前遺傳學檢測（PGT），含有遊離DNA的母體血液用於非侵入性產前檢測（NIPT），羊水和胎兒/胎盤組織用於流產原因的診斷和調查。細胞遺傳學可識別染色體水平的異常，微陣列和SNP陣列可評估拷貝數變異和特定突變，靶向NGS panel可進行多重分析，而全外顯子組測序（WES）和全基因組測序（WGS）則擴展了基因組分析在特定應用中的範圍。

檢測服務可透過內部營運、外包和混合模式提供。檢驗量大的醫院、學術機構和參考實驗室可能擁有內部平台、經過驗證的流程和生物資訊團隊。生育診所、婦產科診所和小規模的醫療機構通常會自行處理病患管理和檢體收集，而將複雜的分析和結果解讀外包。這種模式會影響設備採購、檢查室使用率、檢體物流、週轉時間、資料交換以及集中式服務供應商所獲得的價值百分比。

購買和檢測申請的決策反映了臨床和分析有效性、可報告結果率、提供的檢測範圍、結果報告時間、自動化程度、檢體穩定性、生物資訊效能、與保險公司的合作、法規遵循、諮詢支援、成本效益、技術服務以及供應可靠性。對於胚胎著床前遺傳學檢測 (PGT)，生育診所、切片檢查檢查室、宅配業者和遺傳服務提供者之間的合作尤其重要。對於非侵入性產前檢測 (NIPT) 和攜帶者篩檢，電子訂購、保險覆蓋範圍確認、伴侶追蹤以及清晰的患者解釋可以顯著提高檢測完成率和檢體採集率。

分析能力的提升並不會自動轉化為臨床價值。 NIPT檢測參數的擴展、普遍應用PGT-A、PGT-P以及全基因組生殖檢測，在證據、諮詢要求、知情同意、倫理限制、保險報銷和結果解讀等方面仍存在許多不確定性。因此，永續的業務成長預計將有利於那些將檢驗的技術與臨床適用的適應症、可靠的營運、可負擔的價格、安全的數據管治以及支持生育決策的報告相結合的機構。

對產業的影響

基因篩檢和檢測正在改變生殖醫學，它將基因組資訊納入懷孕前、生育、胚胎、產前和流產等各個環節。產科醫師使用非侵入性產前檢測 (NIPT)篩檢母體血液中常見的胎兒染色體異常，陽性或高風險結果可能需要諮詢或進一步的產前診斷以確診。攜帶者篩檢可以為孕前或孕期遺傳風險的討論提供資訊。不孕症的基因檢測、受精卵分析和復發性流產的評估可以在臨床適用的情況下識別特定的染色體或分子因素。

在輔助生殖技術領域，PGT-A評估胚胎染色體異常，PGT-M針對已知的單基因風險，PGT-SR評估結構重排。這些服務將生育和體外受精（IVF）診所與切片檢查檢查室、宅配業者、基因檢測實驗室、生物資訊學提供者和諮詢師聯繫起來。在一個治療週期內可以獲得多個切片檢查樣本，因此病例數和樣本數的成長可能有所不同。 Vitrolife AB和Yikon Genomics參與胚胎檢測流程，而Natera, Inc.、Myriad Genetics, Inc.、Labcorp、Quest Diagnostics Incorporated和Fulgent Genetics則透過服務網路和專業檢測項目為生殖檢測提供支援。

此產業模式透過檢測服務和單次檢測耗材產生持續收入，其核心是定序、微陣列、細胞遺傳學和自動化系統的部署。 Illumina公司、Thermo Fisher Scientific公司、MGI Tech Co., Ltd.、GeneMind Biosciences公司、Revvity公司、F. Hoffmann-La Roche公司和Takara Bio公司為特定工作流程提供必要的儀器、試劑、檢測方法或軟體。集中式檢查室可以透過高通量處理、標準化的品管系統、與保險公司簽訂的合約、結果解讀的專業知識以及廣泛的轉診網路來實現規模經濟。另一方面，在地化實驗室則能夠更好地控制檢體、數據和結果報告時間。

技術上可行的檢測能否真正完成並獲得回報，取決於保險公司和患者的意願。保險覆蓋範圍標準、預先批准、共同支付、共同支付風險以及體外受精 (IVF) 相關支出都可能降低轉換率和實際價值。區域差異也反映在檢查室認證、專家和諮詢資源、冷鍊和檢體物流、資料管治要求、監管差異以及胚胎檢測的倫理限制等方面。結果解讀的複雜性和臨床效用的不確定性可能會限制非侵入性產前檢測 (NIPT) 的推廣、胚胎植入前遺傳學檢測 (PGT-A) 和胚胎植入前遺傳學檢測 (PGT-P) 的普及以及全基因組方法的應用。具備臨床有效性、可靠的檢體處理、透明的報告、可負擔的價格、諮詢支持和安全的數位連接的醫療機構可以減少這些障礙，並支持負責任地應用這些檢測。由此產生的影響涵蓋檢查室投資和人力資源規劃、保險公司政策、病患就醫途徑以及跨境檢測網路的建立等各個面向。

目錄

調查範圍和定義

第1章：全球生殖健康基因篩檢與檢測市場：產業展望

  • 市場概覽
  • 市場生態系統
    • 生殖遺傳篩檢和檢測流程
    • 目前測試方法狀況
    • 測試實施情況概述
    • 目前關於定價、保險報銷和獲取途徑的最新情況
    • 未來展望
  • 市場趨勢
    • 趨勢：對當前和未來影響的評估
  • 監理情勢
    • 北美洲
    • 歐洲、中東和非洲
    • 亞太地區
    • 拉丁美洲
  • 市場動態
    • 市場促進因素
    • 市場限制因素
    • 市場機遇

第2章 全球生殖健康基因篩檢與檢測市場（依產品/服務分類），2024-2036 年

  • 產品
    • 市場規模及預測
    • 耗材和試劑
    • 裝置
    • 軟體與生物資訊學
  • 服務
    • 市場規模及預測

第3章：2024-2036年全球生殖健康基因篩檢與檢測市場（依檢測類型分類）

  • 攜帶者篩檢
    • 市場規模及預測
    • 擴展攜帶者篩檢
    • 針對性攜帶者篩檢
  • 不孕基因檢測
    • 市場規模及預測
  • 胚胎著床前遺傳學檢測（PGT）
    • 市場規模及預測
    • 胚胎胚胎著床前染色體異常檢測（PGT-A）
    • 針對結構重排的胚胎著床前遺傳學檢測（PGT-SR）
    • 單基因疾病的胚胎著床前遺傳學檢測（PGT-M）
    • 胚胎著床前遺傳學檢測（PGT-P）用於多基因疾病
  • 非侵入性產前檢測
    • 市場規模及預測
  • 其他
    • 市場規模及預測

第4章：2024-2036年全球生殖健康基因篩檢與檢測市場（依遺傳疾病分類）

  • 染色體異常
    • 市場規模及預測
    • 非整倍體
    • 染色體結構異常
    • 拷貝數變異/微缺失與微重複
  • 單基因/單基因疾病
    • 市場規模及預測
    • 體染色體隱性遺傳疾病
    • 體染色體顯性遺傳疾病
    • X連鎖遺傳疾病
  • 其他
    • 市場規模及預測

第5章：2024-2036年全球生殖健康基因篩檢與檢測市場（依技術方法分類）

  • 攜帶者篩檢
    • 市場規模及預測
    • 基於靶向NGS面板的攜帶者篩檢
    • 基於全EXOME定序的帶因者篩檢
    • 基於全基因測序的帶因者篩檢
    • 基於微陣列/SNP基因型鑒定的帶因者篩檢
    • 其他
  • 不孕症的基因檢測
    • 市場規模及預測
    • 細胞遺傳學檢測
    • 基於微陣列/SNP陣列的檢測
    • 使用NGS面板進行檢測
    • 其他
  • 胚胎著床前遺傳學檢測（PGT）
    • 市場規模及預測
    • 基於全基因測序的PGT
    • 基於靶型NGS的PGT
    • 其他
  • 非侵入性產前檢測
    • 市場規模及預測
    • 基於全基因測序/超平行鳥槍定序的非侵入性產前檢測
    • 針對性地進行非侵入性產前檢測
    • 其他
  • 其他
    • 市場規模及預測
    • 使用NGS進行檢測
    • 基於微陣列的偵測
    • 其他方法

第6章：2024-2036年全球生殖健康基因篩檢與檢測市場（依檢體類型分類）

  • 血
    • 市場規模及預測
  • 唾液
    • 市場規模及預測
  • 口腔黏膜拭子
    • 市場規模及預測
  • 胚胎細胞
    • 市場規模及預測
  • 羊水
    • 市場規模及預測
  • 胎兒和胎盤組織
    • 市場規模及預測
  • 其他
    • 市場規模及預測

第7章 全球生殖健康基因篩檢和檢測市場（按最終用戶分類），2024-2036年

  • 醫院
    • 市場規模及預測
  • 不孕症治療和體外受精（IVF）診所
    • 市場規模及預測
  • 診斷、參考和基因檢測實驗室
    • 市場規模及預測
  • 其他
    • 市場規模及預測

第8章：2024-2036年全球生殖健康基因篩檢與檢測市場（按地區分類）

  • 區域概況
  • 北美洲
    • 區域概覽
    • 市場成長促進因素
    • 市場挑戰
    • 在該地區運營的主要公司
    • 分析師意見
    • 市場規模及預測
  • 歐洲、中東和非洲
    • 區域概覽
    • 市場成長促進因素
    • 市場挑戰
    • 在該地區運營的主要公司
    • 分析師意見
    • 市場規模及預測
  • 亞太地區
    • 區域概覽
    • 市場成長促進因素
    • 市場挑戰
    • 在該地區運營的主要公司
    • 分析師意見
    • 市場規模及預測
  • 拉丁美洲
    • 區域概覽
    • 市場成長促進因素
    • 市場挑戰
    • 在該地區運營的主要公司
    • 分析師意見
    • 市場規模及預測

第9章：競爭標桿分析與公司概況

  • 企業市場占有率分析
    • 企業市場占有率分析（按產品）
    • 企業市場占有率分析（服務）
  • 產品基準測試（依公司分類）
    • 透過提供的內容
    • 透過提供的內容
  • 關鍵策略和趨勢
    • 對全球生殖健康基因篩檢和檢測市場的影響
  • 公司簡介
    • Company Offering Both Assays and Instruments
    • Company Offering Assays/Kits
    • 平台提供者
    • 服務供應商
    • 其他公司列表

第10章：調查方法

Product Code: BHP2565SA

This report can be delivered within 1 working day.

Introduction of the Genetic Screening and Testing for Reproductive Health Market

The global genetic screening and testing for reproductive health market, valued at $9,012.6 million in 2025, is projected to reach $24,709.7 million by 2036, registering a compound annual growth rate (CAGR) of 9.73% during 2026-2036.

KEY MARKET STATISTICS
Forecast Period2026 - 2036
2026 Evaluation$9,766.5 Million
2036 Forecast$24,709.7 Million
CAGR9.73%

The market encompasses products, software, and laboratory services used to identify chromosomal abnormalities, inherited conditions, and other genomic factors affecting fertility, embryo viability, pregnancy outcomes, or transmission risk. It supports preconception planning, indication-led infertility evaluation, assisted reproduction, embryo testing, prenatal screening, confirmatory prenatal diagnosis, and investigation of pregnancy loss. Principal test categories comprise carrier screening, infertility genetic testing, preimplantation genetic testing (PGT), non-invasive prenatal testing (NIPT), and other reproductive genetic tests.

Demand is expanding through routine use of cell-free DNA screening in prenatal care, increasing IVF and embryo-testing activity, ancestry-neutral carrier-screening strategies, improving sequencing capacity, and automated bioinformatics and interpretation. NIPT uses maternal blood and remains a screening test; positive or high-risk findings may require counseling and confirmatory diagnostic procedures. Market growth nevertheless depends on reimbursement, patient affordability, evidence of clinical utility, specialist counseling capacity, laboratory quality, regulatory requirements, and ethical acceptance.

Market Introduction

The global genetic screening and testing for reproductive health market includes commercially supplied products and laboratory services that identify genetic factors relevant to conception, fertility, embryo development, pregnancy, and inherited risk. In-scope tests comprise targeted and expanded carrier screening; indication-led infertility genetic testing; PGT for aneuploidy, structural rearrangements, monogenic disorders, and polygenic disorders; NIPT; invasive prenatal diagnosis; products-of-conception testing; and recurrent-pregnancy-loss genetic assessment.

The offering model combines products and services. Products include NGS-based, microarray-based, and other consumables and reagents; attributable sequencing, microarray, and cytogenetic instruments; and software and bioinformatics for quality control, variant analysis, workflow management, interpretation, and reporting. Services encompass sample processing, sequencing or cytogenetic analysis, bioinformatics, variant interpretation, clinical reporting, and testing support. Recurring laboratory-service and consumables expenditure therefore accompanies selective capital investment in analytical platforms.

Technology and specimen selection change across the reproductive pathway. Blood, saliva, and buccal swabs support carrier and infertility testing; embryonic cells obtained through biopsy support PGT; maternal blood containing cell-free DNA supports NIPT; and amniotic fluid or fetal and placental tissue supports diagnostic or pregnancy-loss investigations. Cytogenetics identifies chromosome-level abnormalities, microarray or SNP-array methods assess copy-number changes and selected variants, targeted NGS panels enable multiplexed analysis, and WES or WGS extends genomic breadth in selected applications.

Testing is delivered through local, outsourced, and hybrid models. High-volume hospitals, academic centers, and reference laboratories may maintain in-house platforms, validated pipelines, and bioinformatics teams. Fertility clinics, obstetric practices, and smaller providers commonly retain patient management and sample collection locally while outsourcing complex analysis and interpretation. This structure influences instrument purchasing, laboratory utilization, sample logistics, turnaround time, data exchange, and the share of value captured by centralized service providers.

Purchasing and referral decisions reflect clinical and analytical validation, reportable-result rates, test-menu breadth, turnaround time, automation, sample stability, bioinformatics performance, payer connectivity, regulatory readiness, counseling support, affordability, technical service, and supply reliability. For PGT, coordination among the fertility clinic, biopsy laboratory, courier, and genetics provider is especially important. For NIPT and carrier screening, electronic ordering, benefit verification, partner follow-up, and clear patient communication can materially affect completion and collection.

Broader analytical capability does not automatically create clinical value. Expanded NIPT content, universal PGT-A, PGT-P, and genome-scale reproductive testing remain sensitive to evidence, counseling requirements, consent, ethical restrictions, reimbursement, and interpretation uncertainty. Sustainable commercial growth is therefore expected to favor organizations that match validated technology with clinically appropriate indications, dependable operations, accessible pricing, secure data governance, and reporting that supports reproductive decision-making.

Industrial Impact

Genetic screening and testing is reshaping reproductive care by moving genomic information into preconception, fertility, embryo, prenatal, and pregnancy-loss pathways. Obstetric providers use NIPT to screen maternal blood for common fetal aneuploidies, while positive or high-risk results can lead to counseling and confirmatory prenatal diagnosis. Carrier screening informs inherited-risk discussions before or during pregnancy. Infertility genetic testing, products-of-conception analysis, and recurrent-pregnancy-loss assessment can identify selected chromosomal or molecular contributors where clinically indicated.

Within assisted reproduction, PGT-A assesses embryo aneuploidy, PGT-M addresses known monogenic risk, and PGT-SR evaluates structural rearrangements. These services connect fertility and IVF clinics with biopsy laboratories, couriers, genetic-testing laboratories, bioinformatics providers, and counselors. One treatment cycle can produce several biopsy samples, so case growth and sample growth may differ. Vitrolife AB and Yikon Genomics participate in embryo-testing workflows, while Natera, Inc., Myriad Genetics, Inc., Labcorp, Quest Diagnostics Incorporated, and Fulgent Genetics support reproductive testing through service networks and specialized menus.

The industrial model produces recurring revenue through laboratory services and per-test consumables around an installed base of sequencing, microarray, cytogenetic, and automation systems. Illumina, Inc., Thermo Fisher Scientific Inc., MGI Tech Co., Ltd., GeneMind Biosciences, Revvity, Inc., F. Hoffmann-La Roche Ltd., and Takara Bio Inc. supply enabling instruments, reagents, assays, or software for selected workflows. Centralized laboratories can achieve scale through high-throughput processing, standardized quality systems, payer contracting, interpretation expertise, and broad referral networks, whereas local testing can improve control over samples, data, and turnaround time.

Payers and patients influence whether technically available testing becomes completed and collectible revenue. Coverage criteria, prior authorization, deductibles, self-pay exposure, and IVF-related expenditure can reduce conversion or realized value. Geographic disparities also reflect laboratory accreditation, specialist and counseling capacity, cold-chain or specimen logistics, data-governance requirements, regulatory fragmentation, and ethical restrictions on embryo testing. Interpretation complexity and uncertain clinical utility can constrain expanded NIPT, universal PGT-A, PGT-P, and genome-wide approaches. Providers that combine clinical validity, reliable sample handling, transparent reporting, affordability, counseling support, and secure digital connectivity can reduce these barriers while supporting responsible adoption. The resulting impact extends from laboratory investment and workforce planning to payer policy, patient access, and the organization of cross-border testing networks.

Market Segmentation:

Segmentation 1: By Offering

  • Product
    • Consumables and Reagents
    • Instruments
    • Software and Bioinformatics
  • Services

Services to Lead the Global Genetic Screening and Testing for Reproductive Health Market (by Offering)

Services accounted for the largest market share in 2025 and are expected to grow faster during 2026-2036. Their leadership reflects the clinical complexity of reproductive testing, continued outsourcing by hospitals and fertility clinics, and the need for accredited processing, bioinformatics, interpretation, reporting, payer support, and sample logistics. Specialized laboratories also aggregate testing volume across referral networks, improving utilization of sequencing and cytogenetic infrastructure. Products remain essential to service delivery. Consumables and reagents form the principal recurring product category because each test requires collection, preparation, amplification, sequencing, array, control, or other assay inputs. Instruments and software support capacity, automation, quality control, variant analysis, workflow management, and clinical reporting.

Segmentation 2: By Test Type

  • Carrier Screening
    • Expanded Carrier Screening
    • Targeted Carrier Screening
  • Infertility Genetic Testing
  • Preimplantation Genetic Testing (PGT)
    • Preimplantation Genetic Testing for Aneuploidy (PGT-A)
    • Preimplantation Genetic Testing for Structural Rearrangements (PGT-SR)
    • Preimplantation Genetic Testing for Monogenic Disorders (PGT-M)
    • Preimplantation Genetic Testing for Polygenic Disorders (PGT-P)
  • Non-Invasive Prenatal Testing
  • Others

Non-Invasive Prenatal Testing to Lead the Global Genetic Screening and Testing for Reproductive Health Market (by Test Type)

Non-invasive prenatal testing accounted for the largest test-type share in 2025 and is expected to grow fastest during 2026-2036. Its leadership is supported by maternal-blood collection, strong screening performance for common fetal aneuploidies, an annually renewing pregnancy population, and wider integration of cell-free DNA testing into prenatal care. NIPT remains a screening test; positive or high-risk findings require counseling and may warrant confirmatory diagnostic procedures. Carrier screening is expanding through broader, ancestry-neutral panels, while PGT grows with IVF and embryo-testing activity. Infertility genetic testing remains indication-led. Other tests include invasive prenatal diagnosis, products-of-conception testing, recurrent-pregnancy-loss assessment, and related reproductive genetic applications.

Segmentation 3: By Genetic Disorder

  • Chromosomal Abnormalities
    • Aneuploidies
    • Structural Chromosomal Abnormalities
    • Copy Number Variations/Microdeletions and Microduplications
  • Single-Gene/Monogenic Genetic Disorders
    • Autosomal Recessive Genetic Disorders
    • Autosomal Dominant Genetic Disorders
    • X-linked Genetic Disorders
  • Others

Chromosomal Abnormalities to Lead the Global Genetic Screening and Testing for Reproductive Health Market (by Genetic Disorder)

Chromosomal abnormalities accounted for the largest genetic-disorder share in 2025, supported by NIPT for common fetal aneuploidies, PGT-A, cytogenetic analysis, microarrays, and confirmatory prenatal diagnosis. This segment includes aneuploidies, structural chromosomal abnormalities, and copy-number variations relevant to infertility, embryo viability, fetal development, and pregnancy outcomes. Single-gene and monogenic disorders are expected to grow fastest as expanded carrier screening, targeted NGS panels, PGT-M, WES, and WGS improve access to sequence-level assessment. Testing for autosomal recessive, autosomal dominant, and X-linked disorders is often guided by carrier status, family history, phenotype, or a known pathogenic variant. Growth remains dependent on clinical utility, interpretation quality, counseling, and reimbursement.

Segmentation 4: By Technology Approach

  • Carrier Screening
    • Targeted NGS Panel-Based Carrier Screening
    • Whole-Exome Sequencing-Based Carrier Screening
    • Whole-Genome Sequencing-Based Carrier Screening
    • Microarray/SNP Genotyping-Based Carrier Screening
    • Others
  • Infertility Genetic Testing
    • Cytogenetic Testing
    • Microarray/SNP Array-Based Testing
    • NGS Panel-Based Testing
    • Others
  • Preimplantation Genetic Testing (PGT)
    • Whole-Genome Sequencing-Based PGT
    • Targeted NGS-Based PGT
    • Others
  • Non-Invasive Prenatal Testing
    • Whole-Genome Sequencing/Massively Parallel Shotgun Sequencing-Based NIPT
    • Targeted Approach-Based NIPT
    • Others
  • Others
    • NGS-Based Testing
    • Microarray-Based Testing
    • Other Approaches

Targeted NGS Panel-Based Carrier Screening to Lead the Global Genetic Screening and Testing for Reproductive Health Market (Technology Approach, by Carrier Screening)

At the second level, targeted NGS panel-based carrier screening leads the carrier-screening technology mix in 2025 because it supports multiplexed analysis of clinically selected genes with established workflows and manageable interpretation. Whole-genome sequencing-based carrier screening is expected to grow fastest as coverage improves and laboratories evaluate broader, more uniform analysis; WES is also gaining relevance, while microarray/SNP genotyping and other methods remain useful for established variants and cost-sensitive programs. In infertility genetic testing, NGS panels support simultaneous gene assessment, whereas cytogenetic and microarray/SNP-array methods address chromosome-level and copy-number abnormalities. Targeted NGS leads current PGT workflows, with WGS-based PGT expanding faster. Within NIPT, whole-genome or massively parallel shotgun sequencing is the leading approach; targeted SNP, microarray, rolling-circle amplification, and other approaches support focused or alternative workflows. Other reproductive tests use NGS, microarrays, and additional molecular methods according to clinical indication, sample, validation, cost, and laboratory capability. Across branches, broader coverage raises bioinformatics, counseling, evidence, quality-control, and data-governance requirements, so analytical breadth must be matched with clinically interpretable reporting and regulatory acceptance.

Segmentation 5: By Sample Type

  • Blood
  • Saliva
  • Buccal Swab
  • Embryonic Cells
  • Amniotic Fluid
  • Fetal and Placental Tissue
  • Others

Blood to Lead the Global Genetic Screening and Testing for Reproductive Health Market (by Sample Type)

Blood accounted for the largest sample-type share in 2025 because maternal blood underpins NIPT and blood is also widely used in carrier screening, infertility genetic testing, and selected confirmatory workflows. Established collection procedures, broad platform compatibility, and availability support continued leadership. Saliva is expected to grow fastest as remote and at-home collection, digital ordering, and reduced dependence on phlebotomy expand access to carrier and reproductive-risk testing. Buccal swabs provide another simple DNA source. Embryonic cells remain specific to PGT following biopsy, while amniotic fluid and fetal or placental tissue support confirmatory prenatal diagnosis, products-of-conception testing, and pregnancy-loss investigations. Method selection depends on indication, safety, stability, DNA quality, logistics, and validated laboratory requirements.

Segmentation 6: By End User

  • Hospitals
  • Fertility and IVF Clinics
  • Diagnostic, Reference, and Genetic Testing Laboratories
  • Others

Diagnostic, Reference, and Genetic Testing Laboratories to Lead the Global Genetic Screening and Testing for Reproductive Health Market (by End User)

Diagnostic, reference, and genetic testing laboratories accounted for the largest end-user share in 2025 and are expected to grow fastest during 2026-2036. Their leadership reflects specialized sequencing and cytogenetic platforms, validated assays, accreditation, bioinformatics, qualified interpretation teams, quality systems, and high-throughput processing. Outsourcing from hospitals, obstetric practices, and fertility clinics further concentrates complex testing in centralized laboratories, which can also manage payer requirements, sample logistics, reporting, and provider connectivity. Hospitals coordinate prenatal screening, diagnosis, counseling, and follow-up care, while fertility and IVF clinics generate demand for carrier screening, infertility genetic testing, and PGT. Other users include academic, government, research, and telehealth-enabled organizations.

Segmentation 7: By Region

  • North America
    • U.S.
    • Canada
  • Europe, Middle East and Africa
    • Western Europe
    • Commonwealth of Independent States (CIS)
    • Nordics and South-Eastern/Central Eastern Europe (NSSE)
    • Middle East
    • Africa
    • Rest-of-Europe
  • Asia-Pacific
    • China
    • India
    • Japan
    • South Korea
    • Australia
    • Taiwan
    • Thailand
    • Vietnam
    • Malaysia
    • Rest-of-Asia-Pacific
  • Latin America
    • Brazil
    • Mexico
    • Argentina
    • Colombia
    • Chile
    • Peru
    • Costa Rica
    • Ecuador
    • Panama
    • Puerto Rico
    • Dominican Republic
    • Rest-of-Latin America

North America to Lead the Global Genetic Screening and Testing for Reproductive Health Market (by Region)

North America accounted for the largest regional share in 2025, supported by mature obstetric and fertility-care pathways, extensive sequencing infrastructure, established reimbursement mechanisms, and a dense base of reference laboratories, fertility centers, reproductive genetics companies, and specialized professionals. The U.S. anchors the region through broad access to carrier screening, NIPT, PGT, and indication-led infertility genetic testing. Clinical guidance, ART reporting, payer connectivity, physician awareness, and developed laboratory networks reinforce recurring testing, although coverage and patient cost exposure remain uneven.

Asia-Pacific is expected to grow fastest during 2026-2036. Large reproductive-age and birth populations, expanding IVF utilization, rising awareness of inherited risk, and investment in domestic sequencing platforms, genomic laboratories, and reproductive-health infrastructure support growth. China, India, Japan, South Korea, and Australia are increasing prenatal screening and embryo-testing capacity. Domestic platforms and regional partnerships can improve affordability and service reach, subject to local validation and regulation.

Europe, Middle East and Africa remains significant through public prenatal programs, fertility networks, national genomics initiatives, and specialized laboratories, but reimbursement, ethical frameworks, accreditation, and capabilities differ across subregions. Latin America is expanding through private laboratory investment, fertility-clinic development, and increasing prenatal and carrier-screening use. Across both regions, affordability, specialist availability, sample logistics, data governance, regulation, and public-versus-private access will shape adoption.

Recent Developments in the Genetic Screening and Testing for Reproductive Health Market

  • In July 2026, Myriad Genetics, Inc. launched the FirstGene Multiple Prenatal Screen, extending its reproductive-health portfolio toward simplified prenatal screening workflows. The launch supports integration of multiple screening needs within coordinated sample, interpretation, and reporting pathways for clinicians and patients, while broadening the company's engagement across prenatal care.
  • In June 2026, F. Hoffmann-La Roche Ltd. launched the AXELIOS 1 sequencing platform. The platform creates a longer-term opportunity to support carrier screening, PGT, prenatal testing, and related reproductive genomics, subject to application-specific clinical validation, workflow development, laboratory adoption, and regulatory approval.
  • In May 2026, Natera, Inc. announced an enhanced Panorama workflow with a reduced no-call rate. The update is intended to improve the proportion of maternal samples producing reportable NIPT results and strengthen laboratory efficiency, physician experience, and patient completion.

Demand - Drivers, Challenges, and Opportunities

Market Drivers

Routine Integration of NIPT into Prenatal Care Driving Recurring Testing Volume: Routine integration of NIPT into prenatal care creates recurring demand linked to successive pregnancy cohorts. Each completed maternal-blood screen supports laboratory services, collection materials, logistics, sequencing or alternative detection consumables, bioinformatics, quality control, interpretation, and reporting. Wider eligibility for common-aneuploidy screening can increase physician ordering and patient access, particularly where guidance and organized programs support implementation. However, adoption varies with reimbursement, benefit design, laboratory capacity, and counseling pathways. Testing-volume growth may not translate directly into equal revenue growth because public procurement, payer contracting, competition, lower failure rates, and declining analytical costs can change average realized value per completed test.

Expanding ART Throughput Supporting PGT and Embryo-Biopsy Utilization: Expanding assisted reproductive technology throughput enlarges the clinical base for PGT-A, PGT-M, PGT-SR, embryo-biopsy coordination, and related laboratory analysis. Growth in IVF cycles, blastocyst biopsy, cryopreservation, and frozen-embryo transfer can increase case volume and the number of samples submitted to genetics laboratories. Commercial demand reaches fertility clinics, biopsy laboratories, couriers, sequencing and amplification consumables, bioinformatics, counseling, and reporting. Adoption nevertheless depends on maternal age, indication, embryo yield, evidence, regulation, reimbursement, and patient preference. Market revenue may not rise one-for-one with IVF cycles because some cycles produce no testable embryos, while bundled pricing, multiple biopsies, and laboratory efficiency alter value per case.

Market Challenges

Coverage Gaps and Patient Cost Exposure Limiting Reproductive Genetic-Test Access: Coverage for reproductive genetic testing remains inconsistent across payers, indications, test categories, and countries. Medical-necessity criteria, prior authorization, limited networks, deductibles, coinsurance, denials, and uncertain bills can prevent orders from progressing to completed testing. Public programs may fund common-aneuploidy NIPT or selected carrier conditions while broader panels remain privately insured or self-paid. Cost exposure is influential when PGT is added to an expensive IVF pathway. Laboratories face lower completion, delayed collection, administrative expense, contractual adjustments, and difficult patient balances. Transparent estimates, benefit verification, appeals support, evidence generation, payer contracting, and disciplined test menus can improve access but cannot eliminate geographic and plan-level variation.

Market Opportunities

Expansion of Ancestry-Neutral Carrier Screening into Preconception Care: Ancestry-neutral carrier screening could expand preconception testing beyond individuals identified through family history or traditional ethnic-risk categories. Professional guidance supports offering screening to people who are pregnant or planning pregnancy, creating opportunities in primary care, obstetrics, fertility services, employer benefits, and community channels. Digital education and ordering, saliva collection, coordinated partner testing, couple-level reporting, and tele-genetic counseling can improve completion before pregnancy-related time pressure develops. Adoption is not assured: payer coverage, clinician awareness, panel discipline, variant interpretation, counseling capacity, equitable analytical performance, and referral pathways remain essential. Growth should depend more on reaching unscreened individuals and completing partner pathways than on continually expanding gene counts.

How Can This Report Add Value to an Organization?

Product/Innovation Strategy: Segmentation and testing-volume analysis help organizations prioritize assays, instruments, consumables, software, sample compatibility, automation, interpretation, and unmet workflows across carrier screening, infertility testing, PGT, NIPT, prenatal diagnosis, and pregnancy-loss assessment. The findings also support platform configuration and evidence planning.

Growth/Marketing Strategy: The report helps organizations compare test types, end users, referral channels, payer approaches, partnerships, geographic markets, and local, outsourced, or hybrid testing models. Country-level value and volume forecasts support channel planning, laboratory expansion, benefit strategies, commercial resource allocation, and prioritization of underpenetrated patient pathways.

Competitive Strategy: Company-share analysis, product benchmarking, portfolio breadth, strategic developments, clinical evidence, laboratory reach, installed-base access, regulatory capability, payer connectivity, and service quality help market participants evaluate positioning, partnership opportunities, competitive gaps, acquisition targets, regional strengths, and capabilities needed for sustainable differentiation.

Methodology

Key Considerations and Assumptions in Market Engineering and Validation

  • Years from 2024 to 2036 have been considered for market estimation; 2025 is the base year, and 2026-2036 is the forecast period.
  • Ecosystem inputs cover assay and instrument companies, sequencing-platform providers, software and bioinformatics suppliers, distributors, reproductive genetic-testing laboratories, diagnostic and reference laboratories, hospitals, fertility and IVF clinics, payers, and relevant healthcare professionals.
  • Public-company financial information is drawn from annual reports and investor materials; private-company estimates use disclosed funding, partnerships, operating indicators, and validated research inputs and are not represented as reported revenue.
  • Product and service mapping, testing volume, representative pricing, company revenue, segment splits, and regional validation are triangulated to estimate and forecast the market.

Primary Research

Primary research covers product and platform suppliers, service laboratories, hospitals, fertility and IVF clinics, distributors, genetic counselors, maternal-fetal medicine and reproductive specialists, payers, and laboratory or commercial decision-makers. Relevant roles include executives, product and business-development leaders, laboratory directors, clinical geneticists, bioinformatics specialists, quality and regulatory professionals, procurement heads, and operations managers. Interviews and stakeholder consultation across major regions and testing models support validation of qualitative and quantitative findings.

The key data points intended from primary sources include:

  • validation and triangulation of market numbers and graphs
  • validation of report segmentation and qualitative findings
  • testing volume and PGT-A biopsy-sample volume
  • average selling prices and service pricing
  • competitive landscape, business models, and local versus outsourced testing
  • regional percentage splits

Secondary Research

Open Sources

  • Recognized publications, professional-society guidance, and peer-reviewed literature
  • Government and regulator publications, national registries, and screening programs
  • Annual reports, regulatory filings, and investor presentations of leading market participants
  • Company websites, product documentation, official press releases, and reputable news sources
  • Paid databases

The key data points taken from secondary sources include:

  • market segmentation and percentage-share inputs
  • market values and testing volumes
  • company, portfolio, and strategic-development trends
  • technology, workflow, regulatory, reimbursement, and access developments
  • quantitative inputs used for mathematical and statistical calculations

Key Market Players and Competition Synopsis

The global genetic screening and testing for reproductive health market combines specialized testing-service providers, diversified diagnostic laboratory networks, sequencing-platform companies, fertility-focused laboratories, assay manufacturers, and regional genetic-testing specialists. Service providers compete through clinical validation, test-menu breadth, analytical accuracy, turnaround time, payer access, physician and fertility-clinic relationships, genetic-counseling support, sample logistics, and reporting quality. These capabilities determine whether an order progresses efficiently from collection to an interpretable result and whether the provider can support complex reproductive decisions.

Competition on the product and platform side centers on sequencing performance, instrument placement, reagent economics, workflow automation, assay compatibility, bioinformatics integration, regulatory approvals, and technical support. Thermo Fisher Scientific Inc., Illumina, Inc., Revvity, Inc., GeneMind Biosciences, F. Hoffmann-La Roche Ltd., Takara Bio Inc., and MGI Tech Co., Ltd. participate through instruments, assays, reagents, or software. Natera, Inc., Myriad Genetics, Inc., Labcorp, Quest Diagnostics Incorporated, Vitrolife AB, Fulgent Genetics, and Yikon Genomics compete through testing services or reproductive-health specialization.

Market participants are strengthening their positions through product and service launches, regulatory approvals, partnerships, acquisitions, laboratory expansion, automation, and integrated digital reporting. Competitive advantage increasingly depends on combining reliable workflows with affordability, payer connectivity, clinical evidence, counseling pathways, and reach. Regional providers remain influential because regulation, language, data-localization requirements, reimbursement, referral relationships, and sample logistics vary materially across countries. The market is therefore expected to retain a diverse structure even as consolidation and platform-service partnerships continue.

Some prominent names established in this market are:

  • Thermo Fisher Scientific Inc.
  • Illumina, Inc.
  • Revvity, Inc.
  • GeneMind Biosciences
  • F. Hoffmann-La Roche Ltd.
  • Yikon Genomics
  • Takara Bio Inc.
  • MGI Tech Co., Ltd.
  • Natera, Inc.
  • Myriad Genetics, Inc.
  • Laboratory Corporation of America Holdings
  • Quest Diagnostics Incorporated
  • Vitrolife AB
  • Fulgent Genetics

Table of Contents

Executive Summary

Scope and Definition

1 Global Genetic Screening and Testing for Reproductive Health Market: Industry Outlook

  • 1.1 Market Overview
  • 1.2 Market Ecosystem
    • 1.2.1 Reproductive Genetic Screening and Testing Workflow
      • 1.2.1.1 Patient/Couple Assessment and Genetic Counseling
      • 1.2.1.2 Selection of Reproductive Genetic Test
      • 1.2.1.3 Sample Collection and Preparation
      • 1.2.1.4 Laboratory Processing and Genetic Analysis
      • 1.2.1.5 Bioinformatics, Variant Analysis, and Interpretation
      • 1.2.1.6 Reporting and Post-Test Genetic Counseling
      • 1.2.1.7 Reproductive and Clinical Decision-Making
    • 1.2.2 Testing Methodology Landscape
      • 1.2.2.1 Biochemical
      • 1.2.2.2 Chromosomal
      • 1.2.2.3 Molecular
    • 1.2.3 Testing Adoption Landscape
      • 1.2.3.1 By Test Type
      • 1.2.3.2 By Testing Model (Local vs. Outsourced)
    • 1.2.4 Pricing, Reimbursement, and Access Landscape
    • 1.2.5 Future Outlook
  • 1.3 Market Trends
    • 1.3.1 Trends: Current and Future Impact Assessment
      • 1.3.1.1 Impact Analysis
        • 1.3.1.1.1 Shift from Targeted Panels toward Genome-Scale Reproductive Genetic Testing
        • 1.3.1.1.2 Consolidation of Sequential Tests into Integrated Reproductive Genetic Assays
        • 1.3.1.1.3 Transition from Centralized Send-Out Testing toward Local In-Lab Workflows
  • 1.4 Regulatory Landscape
    • 1.4.1 North America
      • 1.4.1.1 U.S.
      • 1.4.1.2 Canada
    • 1.4.2 Europe, the Middle East and Africa
      • 1.4.2.1 Western Europe
      • 1.4.2.2 Commonwealth of Independent States
        • 1.4.2.2.1 Russia
        • 1.4.2.2.2 Kazakhstan
        • 1.4.2.2.3 Belarus
      • 1.4.2.3 Nordics and South-Eastern/Central Eastern Europe
      • 1.4.2.4 Middle East
      • 1.4.2.5 Africa
    • 1.4.3 Asia-Pacific
      • 1.4.3.1 China
      • 1.4.3.2 Japan
      • 1.4.3.3 India
      • 1.4.3.4 South Korea
      • 1.4.3.5 Taiwan
      • 1.4.3.6 Thailand
      • 1.4.3.7 Vietnam
      • 1.4.3.8 Malaysia
      • 1.4.3.9 Australia
    • 1.4.4 Latin America
      • 1.4.4.1 Brazil
      • 1.4.4.2 Mexico
      • 1.4.4.3 Argentina
      • 1.4.4.4 Chile
      • 1.4.4.5 Colombia
      • 1.4.4.6 Costa Rica
  • 1.5 Market Dynamics
    • 1.5.1 Market Drivers
      • 1.5.1.1 Routine Integration of NIPT into Prenatal Care Driving Recurring Testing Volume
      • 1.5.1.2 Expanding ART Throughput Supporting PGT and Embryo-Biopsy Utilization
      • 1.5.1.3 Integration of Carrier Screening into Prenatal and Fertility-Care Workflows
    • 1.5.2 Market Restraints
      • 1.5.2.1 Coverage Gaps and Patient Cost Exposure Limiting Reproductive Genetic-Test Access
      • 1.5.2.2 Clinical-Utility Uncertainty Restricting Routine PGT-A and Expanded NIPT Adoption
      • 1.5.2.3 Regulatory and Ethical Restrictions Limiting PGT Availability and Commercialization
    • 1.5.3 Market Opportunities
      • 1.5.3.1 Expansion of Ancestry-Neutral Carrier Screening into Preconception Care
      • 1.5.3.2 Genomic Testing for Unexplained Infertility and Pregnancy Loss
      • 1.5.3.3 Clinical Expansion of Monogenic and Genome-Wide Prenatal Screening

2 Global Genetic Screening and Testing for Reproductive Health Market (by Offering), $Million, 2024-2036

  • 2.1 Product
    • 2.1.1 Market Sizing and Forecast
    • 2.1.2 Consumables and Reagents
      • 2.1.2.1 Market Sizing and Forecast
      • 2.1.2.2 NGS-Based Consumables and Reagents
      • 2.1.2.3 Market Sizing and Forecast
      • 2.1.2.4 Microarray-Based Consumables and Reagents
      • 2.1.2.5 Market Sizing and Forecast
      • 2.1.2.6 Other Consumables and Reagents
      • 2.1.2.7 Market Sizing and Forecast
    • 2.1.3 Instruments
      • 2.1.3.1 Market Sizing and Forecast
    • 2.1.4 Software and Bioinformatics
      • 2.1.4.1 Market Sizing and Forecast
  • 2.2 Services
    • 2.2.1 Market Sizing and Forecast

3 Global Genetic Screening and Testing for Reproductive Health Market (by Test Type), $Million, 2024-2036

  • 3.1 Carrier Screening
    • 3.1.1 Market Sizing and Forecast
    • 3.1.2 Expanded Carrier Screening
      • 3.1.2.1 Market Sizing and Forecast
    • 3.1.3 Targeted Carrier Screening
      • 3.1.3.1 Market Sizing and Forecast
  • 3.2 Infertility Genetic Testing
    • 3.2.1 Market Sizing and Forecast
  • 3.3 Preimplantation Genetic Testing (PGT)
    • 3.3.1 Market Sizing and Forecast
    • 3.3.2 Preimplantation Genetic Testing for Aneuploidy (PGT-A)
      • 3.3.2.1 Market Sizing and Forecast
    • 3.3.3 Preimplantation Genetic Testing for Structural Rearrangements (PGT-SR)
      • 3.3.3.1 Market Sizing and Forecast
    • 3.3.4 Preimplantation Genetic Testing for Monogenic Disorders (PGT-M)
      • 3.3.4.1 Market Sizing and Forecast
    • 3.3.5 Preimplantation Genetic Testing for Polygenic Disorders (PGT-P)
      • 3.3.5.1 Market Sizing and Forecast
  • 3.4 Non-Invasive Prenatal Testing
    • 3.4.1 Market Sizing and Forecast
  • 3.5 Others
    • 3.5.1 Market Sizing and Forecast

4 Global Genetic Screening and Testing for Reproductive Health Market (by Genetic Disorder), $Million, 2024-2036

  • 4.1 Chromosomal Abnormalities
    • 4.1.1 Market Sizing and Forecast
    • 4.1.2 Aneuploidies
      • 4.1.2.1 Market Sizing and Forecast
    • 4.1.3 Structural Chromosomal Abnormalities
      • 4.1.3.1 Market Sizing and Forecast
    • 4.1.4 Copy Number Variations/Microdeletions and Microduplications
      • 4.1.4.1 Market Sizing and Forecast
  • 4.2 Single-Gene/Monogenic Genetic Disorders
    • 4.2.1 Market Sizing and Forecast
    • 4.2.2 Autosomal Recessive Genetic Disorders
      • 4.2.2.1 Market Sizing and Forecast
    • 4.2.3 Autosomal Dominant Genetic Disorders
      • 4.2.3.1 Market Sizing and Forecast
    • 4.2.4 X-Linked Genetic Disorders
      • 4.2.4.1 Market Sizing and Forecast
  • 4.3 Others
    • 4.3.1 Market Sizing and Forecast

5 Global Genetic Screening and Testing for Reproductive Health Market (by Technology Approach), $Million, 2024-2036

  • 5.1 Carrier Screening
    • 5.1.1 Market Sizing and Forecast
    • 5.1.2 Targeted NGS Panel-Based Carrier Screening
      • 5.1.2.1 Market Sizing and Forecast
    • 5.1.3 Whole-Exome Sequencing-Based Carrier Screening
      • 5.1.3.1 Market Sizing and Forecast
    • 5.1.4 Whole-Genome Sequencing-Based Carrier Screening
      • 5.1.4.1 Market Sizing and Forecast
    • 5.1.5 Microarray/SNP Genotyping-Based Carrier Screening
      • 5.1.5.1 Market Sizing and Forecast
    • 5.1.6 Others
      • 5.1.6.1 Market Sizing and Forecast
  • 5.2 Infertility Genetic Testing
    • 5.2.1 Market Sizing and Forecast
    • 5.2.2 Cytogenetic Testing
      • 5.2.2.1 Market Sizing and Forecast
    • 5.2.3 Microarray/SNP Array-Based Testing
      • 5.2.3.1 Market Sizing and Forecast
    • 5.2.4 NGS Panel-Based Testing
      • 5.2.4.1 Market Sizing and Forecast
    • 5.2.5 Others
      • 5.2.5.1 Market Sizing and Forecast
  • 5.3 Preimplantation Genetic Testing (PGT)
    • 5.3.1 Market Sizing and Forecast
    • 5.3.2 Whole-Genome Sequencing-Based PGT
      • 5.3.2.1 Market Sizing and Forecast
    • 5.3.3 Targeted NGS-Based PGT
      • 5.3.3.1 Market Sizing and Forecast
    • 5.3.4 Others
      • 5.3.4.1 Market Sizing and Forecast
  • 5.4 Non-Invasive Prenatal Testing
    • 5.4.1 Market Sizing and Forecast
    • 5.4.2 Whole-Genome Sequencing/Massively Parallel Shotgun Sequencing-Based NIPT
      • 5.4.2.1 Market Sizing and Forecast
    • 5.4.3 Targeted Approach-Based NIPT
      • 5.4.3.1 Market Sizing and Forecast
      • 5.4.3.2 SNP Analysis
      • 5.4.3.3 Market Sizing and Forecast
      • 5.4.3.4 Microarray Analysis
      • 5.4.3.5 Market Sizing and Forecast
      • 5.4.3.6 Rolling Circle Amplification-Based NIPT
      • 5.4.3.7 Market Sizing and Forecast
    • 5.4.4 Others
      • 5.4.4.1 Market Sizing and Forecast
  • 5.5 Others
    • 5.5.1 Market Sizing and Forecast
    • 5.5.2 NGS-Based Testing
      • 5.5.2.1 Market Sizing and Forecast
    • 5.5.3 Microarray-Based Testing
      • 5.5.3.1 Market Sizing and Forecast
    • 5.5.4 Other Approaches
      • 5.5.4.1 Market Sizing and Forecast

6 Global Genetic Screening and Testing for Reproductive Health Market (by Sample Type), $Million, 2024-2036

  • 6.1 Blood
    • 6.1.1 Market Sizing and Forecast
  • 6.2 Saliva
    • 6.2.1 Market Sizing and Forecast
  • 6.3 Buccal Swab
    • 6.3.1 Market Sizing and Forecast
  • 6.4 Embryonic Cells
    • 6.4.1 Market Sizing and Forecast
  • 6.5 Amniotic Fluid
    • 6.5.1 Market Sizing and Forecast
  • 6.6 Fetal and Placental Tissue
    • 6.6.1 Market Sizing and Forecast
  • 6.7 Others
    • 6.7.1 Market Sizing and Forecast

7 Global Genetic Screening and Testing for Reproductive Health Market (by End User), $Million, 2024-2036

  • 7.1 Hospitals
    • 7.1.1 Market Sizing and Forecast
  • 7.2 Fertility and IVF Clinics
    • 7.2.1 Market Sizing and Forecast
  • 7.3 Diagnostic, Reference, and Genetic Testing Laboratories
    • 7.3.1 Market Sizing and Forecast
  • 7.4 Others
    • 7.4.1 Market Sizing and Forecast

8 Global Genetic Screening and Testing for Reproductive Health Market (by Region), $Million, 2024-2036

  • 8.1 Regional Summary
  • 8.2 North America
    • 8.2.1 Regional Overview
    • 8.2.2 Driving Factors for Market Growth
    • 8.2.3 Factors Challenging the Market
    • 8.2.4 Key Companies Operating in the Region
    • 8.2.5 Analyst View
    • 8.2.6 Market Sizing and Forecast
      • 8.2.6.1 North America Genetic Screening and Testing for Reproductive Health Market, by Country
      • 8.2.6.2 North America Genetic Screening and Testing for Reproductive Health Market, by Testing Volume
      • 8.2.6.3 North America Genetic Screening and Testing for Reproductive Health Market, by Testing Volume, by Preimplantation Genetic Testing (PGT)
      • 8.2.6.4 North America Genetic Screening and Testing for Reproductive Health Market, Testing Volume, by PGT-A Biopsy Samples Tested
      • 8.2.6.5 North America Genetic Screening and Testing for Reproductive Health Market, by Offering
      • 8.2.6.6 North America Genetic Screening and Testing for Reproductive Health Market, by Products
      • 8.2.6.7 North America Genetic Screening and Testing for Reproductive Health Market, by Test Type
      • 8.2.6.8 North America Genetic Screening and Testing for Reproductive Health Market, Test Type, (by Carrier Screening)
      • 8.2.6.9 North America Genetic Screening and Testing for Reproductive Health Market, Test Type, (by Preimplantation Genetic Testing (PGT))
      • 8.2.6.10 North America Genetic Screening and Testing for Reproductive Health Market, By Technology Approach
      • 8.2.6.11 North America Genetic Screening and Testing for Reproductive Health Market, Technology Approach, By Carrier Screening
      • 8.2.6.12 North America Genetic Screening and Testing for Reproductive Health Market, Technology Approach, By Infertility Genetic Testing
      • 8.2.6.13 North America Genetic Screening and Testing for Reproductive Health Market, Technology Approach, By Preimplantation Genetic Testing (PGT)
      • 8.2.6.14 North America Genetic Screening and Testing for Reproductive Health Market, Technology Approach, By Non-Invasive Prenatal Testing
      • 8.2.6.15 North America Genetic Screening and Testing for Reproductive Health Market, Technology Approach, By Others
        • 8.2.6.15.1 U.S.
          • 8.2.6.15.1.1 Country Overview
          • 8.2.6.15.1.2 Driving Factors for Market Growth
          • 8.2.6.15.1.3 Factors Challenging the Market
          • 8.2.6.15.1.4 Key Companies Operating in the Country
          • 8.2.6.15.1.5 Analyst View
          • 8.2.6.15.1.6 Market Sizing and Forecast
        • 8.2.6.15.2 Canada
          • 8.2.6.15.2.1 Country Overview
          • 8.2.6.15.2.2 Driving Factors for Market Growth
          • 8.2.6.15.2.3 Factors Challenging the Market
          • 8.2.6.15.2.4 Key Companies Operating in the Country
          • 8.2.6.15.2.5 Analyst View
          • 8.2.6.15.2.6 Market Sizing and Forecast
  • 8.3 Europe, Middle East and Africa
    • 8.3.1 Regional Overview
    • 8.3.2 Driving Factors for Market Growth
    • 8.3.3 Factors Challenging the Market
    • 8.3.4 Key Companies Operating in the Region
    • 8.3.5 Analyst View
    • 8.3.6 Market Sizing and Forecast
      • 8.3.6.1 Europe, Middle East and Africa Genetic Screening and Testing for Reproductive Health Market, by Country
      • 8.3.6.2 Europe, Middle East and Africa Genetic Screening and Testing for Reproductive Health Market, by Testing Volume
      • 8.3.6.3 Europe, Middle East and Africa Genetic Screening and Testing for Reproductive Health Market, by Testing Volume, by Preimplantation Genetic Testing (PGT)
      • 8.3.6.4 Europe, Middle East and Africa Genetic Screening and Testing for Reproductive Health Market, Testing Volume, by PGT-A Biopsy Samples Tested
      • 8.3.6.5 Europe, Middle East and Africa Genetic Screening and Testing for Reproductive Health Market, by Offering
      • 8.3.6.6 Europe, Middle East and Africa Genetic Screening and Testing for Reproductive Health Market, by Products
      • 8.3.6.7 Europe, Middle East and Africa Genetic Screening and Testing for Reproductive Health Market, by Test Type
      • 8.3.6.8 Europe, Middle East and Africa Genetic Screening and Testing for Reproductive Health Market, Test Type, (by Carrier Screening)
      • 8.3.6.9 Europe, Middle East and Africa Genetic Screening and Testing for Reproductive Health Market, Test Type, (by Preimplantation Genetic Testing (PGT))
      • 8.3.6.10 Europe, Middle East and Africa Genetic Screening and Testing for Reproductive Health Market, By Technology Approach
      • 8.3.6.11 Europe, Middle East and Africa Genetic Screening and Testing for Reproductive Health Market, Technology Approach, By Carrier Screening
      • 8.3.6.12 Europe, Middle East and Africa Genetic Screening and Testing for Reproductive Health Market, Technology Approach, By Infertility Genetic Testing
      • 8.3.6.13 Europe, Middle East and Africa Genetic Screening and Testing for Reproductive Health Market, Technology Approach, By Preimplantation Genetic Testing (PGT)
      • 8.3.6.14 Europe, Middle East and Africa Genetic Screening and Testing for Reproductive Health Market, Technology Approach, By Non-Invasive Prenatal Testing
      • 8.3.6.15 Europe, Middle East and Africa Genetic Screening and Testing for Reproductive Health Market, Technology Approach, By Others
        • 8.3.6.15.1 Western Europe
          • 8.3.6.15.1.1 Country Overview
          • 8.3.6.15.1.2 Driving Factors for Market Growth
          • 8.3.6.15.1.3 Factors Challenging the Market
          • 8.3.6.15.1.4 Key Companies Operating in the Sub-Region
          • 8.3.6.15.1.5 Analyst View
          • 8.3.6.15.1.6 Market Sizing and Forecast
        • 8.3.6.15.2 Commonwealth of Independent States (CIS)
          • 8.3.6.15.2.1 Country Overview
          • 8.3.6.15.2.2 Driving Factors for Market Growth
          • 8.3.6.15.2.3 Factors Challenging the Market
          • 8.3.6.15.2.4 Key Companies Operating in the Sub-Region
          • 8.3.6.15.2.5 Analyst View
          • 8.3.6.15.2.6 Market Sizing and Forecast
        • 8.3.6.15.3 Nordics and South-Eastern/Central Eastern Europe (NSSE)
          • 8.3.6.15.3.1 Country Overview
          • 8.3.6.15.3.2 Driving Factors for Market Growth
          • 8.3.6.15.3.3 Factors Challenging the Market
          • 8.3.6.15.3.4 Analyst View
          • 8.3.6.15.3.5 Market Sizing and Forecast
        • 8.3.6.15.4 Middle East
          • 8.3.6.15.4.1 Country Overview
          • 8.3.6.15.4.2 Driving Factors for Market Growth
          • 8.3.6.15.4.3 Factors Challenging the Market
          • 8.3.6.15.4.4 Key Companies Operating in the Sub-Region
          • 8.3.6.15.4.5 Analyst View
          • 8.3.6.15.4.6 Market Sizing and Forecast
        • 8.3.6.15.5 Africa
          • 8.3.6.15.5.1 Country Overview
          • 8.3.6.15.5.2 Driving Factors for Market Growth
          • 8.3.6.15.5.3 Factors Challenging the Market
          • 8.3.6.15.5.4 Key Companies Operating in the Sub-Region
          • 8.3.6.15.5.5 Analyst View
          • 8.3.6.15.5.6 Market Sizing and Forecast
  • 8.4 Asia-Pacific
    • 8.4.1 Regional Overview
    • 8.4.2 Driving Factors for Market Growth
    • 8.4.3 Factors Challenging the Market
    • 8.4.4 Key Companies Operating in the Region
    • 8.4.5 Analyst View
    • 8.4.6 Market Sizing and Forecast
      • 8.4.6.1 Asia-Pacific Genetic Screening and Testing for Reproductive Health Market, by Country
      • 8.4.6.2 Asia-Pacific Genetic Screening and Testing for Reproductive Health Market, by Testing Volume
      • 8.4.6.3 Asia-Pacific Genetic Screening and Testing for Reproductive Health Market, by Testing Volume, by Preimplantation Genetic Testing (PGT)
      • 8.4.6.4 Asia-Pacific Genetic Screening and Testing for Reproductive Health Market, Testing Volume, by PGT-A Biopsy Samples Tested
      • 8.4.6.5 Asia-Pacific Genetic Screening and Testing for Reproductive Health Market, by Offering
      • 8.4.6.6 Asia-Pacific Genetic Screening and Testing for Reproductive Health Market, by Products
      • 8.4.6.7 Asia-Pacific Genetic Screening and Testing for Reproductive Health Market, by Test Type
      • 8.4.6.8 Asia-Pacific Genetic Screening and Testing for Reproductive Health Market, Test Type, (by Carrier Screening)
      • 8.4.6.9 Asia-Pacific Genetic Screening and Testing for Reproductive Health Market, Test Type, (by Preimplantation Genetic Testing (PGT))
      • 8.4.6.10 Asia-Pacific Genetic Screening and Testing for Reproductive Health Market, By Technology Approach
      • 8.4.6.11 Asia-Pacific Genetic Screening and Testing for Reproductive Health Market, Technology Approach, By Carrier Screening
      • 8.4.6.12 Asia-Pacific Genetic Screening and Testing for Reproductive Health Market, Technology Approach, By Infertility Genetic Testing
      • 8.4.6.13 Asia-Pacific Genetic Screening and Testing for Reproductive Health Market, Technology Approach, By Preimplantation Genetic Testing (PGT)
      • 8.4.6.14 Asia-Pacific Genetic Screening and Testing for Reproductive Health Market, Technology Approach, By Non-Invasive Prenatal Testing
      • 8.4.6.15 Asia-Pacific Genetic Screening and Testing for Reproductive Health Market, Technology Approach, By Others
        • 8.4.6.15.1 China
          • 8.4.6.15.1.1 Country Overview
          • 8.4.6.15.1.2 Driving Factors for Market Growth
          • 8.4.6.15.1.3 Factors Challenging the Market
          • 8.4.6.15.1.4 Key Companies Operating in the Country
          • 8.4.6.15.1.5 Analyst View
          • 8.4.6.15.1.6 Market Sizing and Forecast
        • 8.4.6.15.2 India
          • 8.4.6.15.2.1 Country Overview
          • 8.4.6.15.2.2 Driving Factors for Market Growth
          • 8.4.6.15.2.3 Factors Challenging the Market
          • 8.4.6.15.2.4 Key Companies Operating in the Country
          • 8.4.6.15.2.5 Analyst View
          • 8.4.6.15.2.6 Market Sizing and Forecast
        • 8.4.6.15.3 Japan
          • 8.4.6.15.3.1 Country Overview
          • 8.4.6.15.3.2 Driving Factors for Market Growth
          • 8.4.6.15.3.3 Factors Challenging the Market
          • 8.4.6.15.3.4 Key Companies Operating in the Country
          • 8.4.6.15.3.5 Analyst View
          • 8.4.6.15.3.6 Market Sizing and Forecast
        • 8.4.6.15.4 South Korea
          • 8.4.6.15.4.1 Country Overview
          • 8.4.6.15.4.2 Driving Factors for Market Growth
          • 8.4.6.15.4.3 Factors Challenging the Market
          • 8.4.6.15.4.4 Key Companies Operating in the Country
          • 8.4.6.15.4.5 Analyst View
          • 8.4.6.15.4.6 Market Sizing and Forecast
        • 8.4.6.15.5 Australia
          • 8.4.6.15.5.1 Country Overview
          • 8.4.6.15.5.2 Driving Factors for Market Growth
          • 8.4.6.15.5.3 Factors Challenging the Market
          • 8.4.6.15.5.4 Key Companies Operating in the Country
          • 8.4.6.15.5.5 Analyst View
          • 8.4.6.15.5.6 Market Sizing and Forecast
        • 8.4.6.15.6 Taiwan
          • 8.4.6.15.6.1 Country Overview
          • 8.4.6.15.6.2 Driving Factors for Market Growth
          • 8.4.6.15.6.3 Factors Challenging the Market
          • 8.4.6.15.6.4 Key Companies Operating in the Country
          • 8.4.6.15.6.5 Analyst View
          • 8.4.6.15.6.6 Market Sizing and Forecast
        • 8.4.6.15.7 Thailand
          • 8.4.6.15.7.1 Country Overview
          • 8.4.6.15.7.2 Driving Factors for Market Growth
          • 8.4.6.15.7.3 Factors Challenging the Market
          • 8.4.6.15.7.4 Key Companies Operating in the Country
          • 8.4.6.15.7.5 Analyst View
          • 8.4.6.15.7.6 Market Sizing and Forecast
        • 8.4.6.15.8 Vietnam
          • 8.4.6.15.8.1 Country Overview
          • 8.4.6.15.8.2 Driving Factors for Market Growth
          • 8.4.6.15.8.3 Factors Challenging the Market
          • 8.4.6.15.8.4 Key Companies Operating in the Country
          • 8.4.6.15.8.5 Analyst View
          • 8.4.6.15.8.6 Market Sizing and Forecast
        • 8.4.6.15.9 Malaysia
          • 8.4.6.15.9.1 Country Overview
          • 8.4.6.15.9.2 Driving Factors for Market Growth
          • 8.4.6.15.9.3 Factors Challenging the Market
          • 8.4.6.15.9.4 Key Companies Operating in the Country
          • 8.4.6.15.9.5 Analyst View
          • 8.4.6.15.9.6 Market Sizing and Forecast
        • 8.4.6.15.10 Rest-of-Asia-Pacific
          • 8.4.6.15.10.1 Country Overview
          • 8.4.6.15.10.2 Driving Factors for Market Growth
          • 8.4.6.15.10.3 Factors Challenging the Market
          • 8.4.6.15.10.4 Key Companies Operating in the Country
          • 8.4.6.15.10.5 Analyst View
          • 8.4.6.15.10.6 Market Sizing and Forecast
  • 8.5 Latin America
    • 8.5.1 Regional Overview
    • 8.5.2 Driving Factors for Market Growth
    • 8.5.3 Factors Challenging the Market
    • 8.5.4 Key Companies Operating in the Region
    • 8.5.5 Analyst View
    • 8.5.6 Market Sizing and Forecast
      • 8.5.6.1 Latin America Genetic Screening and Testing for Reproductive Health Market, by Country
      • 8.5.6.2 Latin America Genetic Screening and Testing for Reproductive Health Market, by Testing Volume
      • 8.5.6.3 Latin America Genetic Screening and Testing for Reproductive Health Market, by Testing Volume, by Preimplantation Genetic Testing (PGT)
      • 8.5.6.4 Latin America Genetic Screening and Testing for Reproductive Health Market, Testing Volume, by PGT-A Biopsy Samples Tested
      • 8.5.6.5 Latin America Genetic Screening and Testing for Reproductive Health Market, by Offering
      • 8.5.6.6 Latin America Genetic Screening and Testing for Reproductive Health Market, by Products
      • 8.5.6.7 Latin America Genetic Screening and Testing for Reproductive Health Market, by Test Type
      • 8.5.6.8 Latin America Genetic Screening and Testing for Reproductive Health Market, Test Type, (by Carrier Screening)
      • 8.5.6.9 Latin America Genetic Screening and Testing for Reproductive Health Market, Test Type, (by Preimplantation Genetic Testing (PGT))
      • 8.5.6.10 Latin America Genetic Screening and Testing for Reproductive Health Market, By Technology Approach
      • 8.5.6.11 Latin America Genetic Screening and Testing for Reproductive Health Market, Technology Approach, By Carrier Screening
      • 8.5.6.12 Latin America Genetic Screening and Testing for Reproductive Health Market, Technology Approach, By Infertility Genetic Testing
      • 8.5.6.13 Latin America Genetic Screening and Testing for Reproductive Health Market, Technology Approach, By Preimplantation Genetic Testing (PGT)
      • 8.5.6.14 Latin America Genetic Screening and Testing for Reproductive Health Market, Technology Approach, By Non-Invasive Prenatal Testing
      • 8.5.6.15 Latin America Genetic Screening and Testing for Reproductive Health Market, Technology Approach, By Others
        • 8.5.6.15.1 Brazil
          • 8.5.6.15.1.1 Country Overview
          • 8.5.6.15.1.2 Driving Factors for Market Growth
          • 8.5.6.15.1.3 Factors Challenging the Market
          • 8.5.6.15.1.4 Key Companies Operating in the Country
          • 8.5.6.15.1.5 Analyst View
          • 8.5.6.15.1.6 Market Sizing and Forecast
        • 8.5.6.15.2 Mexico
          • 8.5.6.15.2.1 Country Overview
          • 8.5.6.15.2.2 Driving Factors for Market Growth
          • 8.5.6.15.2.3 Factors Challenging the Market
          • 8.5.6.15.2.4 Key Companies Operating in the Country
          • 8.5.6.15.2.5 Analyst View
          • 8.5.6.15.2.6 Market Sizing and Forecast
        • 8.5.6.15.3 Argentina
          • 8.5.6.15.3.1 Country Overview
          • 8.5.6.15.3.2 Driving Factors for Market Growth
          • 8.5.6.15.3.3 Factors Challenging the Market
          • 8.5.6.15.3.4 Key Companies Operating in the Country
          • 8.5.6.15.3.5 Analyst View
          • 8.5.6.15.3.6 Market Sizing and Forecast
        • 8.5.6.15.4 Colombia
          • 8.5.6.15.4.1 Country Overview
          • 8.5.6.15.4.2 Driving Factors for Market Growth
          • 8.5.6.15.4.3 Factors Challenging the Market
          • 8.5.6.15.4.4 Key Companies Operating in the Country
          • 8.5.6.15.4.5 Analyst View
          • 8.5.6.15.4.6 Market Sizing and Forecast
        • 8.5.6.15.5 Chile
          • 8.5.6.15.5.1 Country Overview
          • 8.5.6.15.5.2 Driving Factors for Market Growth
          • 8.5.6.15.5.3 Factors Challenging the Market
          • 8.5.6.15.5.4 Key Companies Operating in the Country
          • 8.5.6.15.5.5 Analyst View
          • 8.5.6.15.5.6 Market Sizing and Forecast
        • 8.5.6.15.6 Peru
          • 8.5.6.15.6.1 Country Overview
          • 8.5.6.15.6.2 Driving Factors for Market Growth
          • 8.5.6.15.6.3 Factors Challenging the Market
          • 8.5.6.15.6.4 Key Companies Operating in the Country
          • 8.5.6.15.6.5 Analyst View
          • 8.5.6.15.6.6 Market Sizing and Forecast
        • 8.5.6.15.7 Costa Rica
          • 8.5.6.15.7.1 Country Overview
          • 8.5.6.15.7.2 Driving Factors for Market Growth
          • 8.5.6.15.7.3 Factors Challenging the Market
          • 8.5.6.15.7.4 Key Companies Operating in the Country
          • 8.5.6.15.7.5 Analyst View
          • 8.5.6.15.7.6 Market Sizing and Forecast
        • 8.5.6.15.8 Ecuador
          • 8.5.6.15.8.1 Country Overview
          • 8.5.6.15.8.2 Driving Factors for Market Growth
          • 8.5.6.15.8.3 Factors Challenging the Market
          • 8.5.6.15.8.4 Key Companies Operating in the Country
          • 8.5.6.15.8.5 Analyst View
          • 8.5.6.15.8.6 Market Sizing and Forecast
        • 8.5.6.15.9 Panama
          • 8.5.6.15.9.1 Country Overview
          • 8.5.6.15.9.2 Driving Factors for Market Growth
          • 8.5.6.15.9.3 Factors Challenging the Market
          • 8.5.6.15.9.4 Key Companies Operating in the Country
          • 8.5.6.15.9.5 Analyst View
          • 8.5.6.15.9.6 Market Sizing and Forecast
        • 8.5.6.15.10 Puerto Rico
          • 8.5.6.15.10.1 Country Overview
          • 8.5.6.15.10.2 Driving Factors for Market Growth
          • 8.5.6.15.10.3 Factors Challenging the Market
          • 8.5.6.15.10.4 Key Companies Operating in the Country
          • 8.5.6.15.10.5 Analyst View
          • 8.5.6.15.10.6 Market Sizing and Forecast
        • 8.5.6.15.11 Dominican Republic
          • 8.5.6.15.11.1 Country Overview
          • 8.5.6.15.11.2 Driving Factors for Market Growth
          • 8.5.6.15.11.3 Factors Challenging the Market
          • 8.5.6.15.11.4 Key Companies Operating in the Country
          • 8.5.6.15.11.5 Analyst View
          • 8.5.6.15.11.6 Market Sizing and Forecast
        • 8.5.6.15.12 Rest-of-Latin America
          • 8.5.6.15.12.1 Country Overview
          • 8.5.6.15.12.2 Driving Factors for Market Growth
          • 8.5.6.15.12.3 Factors Challenging the Market
          • 8.5.6.15.12.4 Key Companies Operating in the Country
          • 8.5.6.15.12.5 Analyst View
          • 8.5.6.15.12.6 Market Sizing and Forecast

9 Competitive Benchmarking and Company Profiles

  • 9.1 Company Share Analysis
    • 9.1.1 Company Share Analysis (Product)
    • 9.1.2 Company Share Analysis (Services)
  • 9.2 Product Benchmarking (by Company)
    • 9.2.1 By Offering
    • 9.2.2 By Offering
  • 9.3 Key Strategies and Developments
    • 9.3.1 Impact on the Global Genetic Screening and Testing for Reproductive Health Market
  • 9.4 Company Profiles
    • 9.4.1 Company Offering Both Assays and Instruments
      • 9.4.1.1 Thermo Fisher Scientific Inc.
        • 9.4.1.1.1 Overview
        • 9.4.1.1.2 Top Product/Service Portfolio
        • 9.4.1.1.3 Top Competitors
        • 9.4.1.1.4 Key Personnel
        • 9.4.1.1.5 Analyst View
      • 9.4.1.2 Illumina, Inc.
        • 9.4.1.2.1 Overview
        • 9.4.1.2.2 Top Product/Service Portfolio
        • 9.4.1.2.3 Top Competitors
        • 9.4.1.2.4 Key Personnel
        • 9.4.1.2.5 Analyst View
      • 9.4.1.3 Revvity, Inc.
        • 9.4.1.3.1 Overview
        • 9.4.1.3.2 Top Product/Service Portfolio
        • 9.4.1.3.3 Top Competitors
        • 9.4.1.3.4 Key Personnel
        • 9.4.1.3.5 Analyst View
      • 9.4.1.4 GeneMind Biosciences Co., Ltd
        • 9.4.1.4.1 Overview
        • 9.4.1.4.2 Top Product/Service Portfolio
        • 9.4.1.4.3 Top Competitors
        • 9.4.1.4.4 Key Personnel
        • 9.4.1.4.5 Analyst View
      • 9.4.1.5 F. Hoffmann-La Roche Ltd.
        • 9.4.1.5.1 Overview
        • 9.4.1.5.2 Top Product/Service Portfolio
        • 9.4.1.5.3 Top Competitors
        • 9.4.1.5.4 Key Personnel
        • 9.4.1.5.5 Analyst View
    • 9.4.2 Company Offering Assays/ Kits
      • 9.4.2.1 Yikon Genomics
        • 9.4.2.1.1 Overview
        • 9.4.2.1.2 Top Product/Service Portfolio
        • 9.4.2.1.3 Top Competitors
        • 9.4.2.1.4 Key Personnel
        • 9.4.2.1.5 Analyst View
      • 9.4.2.2 Takara Bio Inc.
        • 9.4.2.2.1 Overview
        • 9.4.2.2.2 Top Product/Service Portfolio
        • 9.4.2.2.3 Top Competitors
        • 9.4.2.2.4 Key Personnel
        • 9.4.2.2.5 Analyst View
    • 9.4.3 Platform Providers
      • 9.4.3.1 MGI Tech Co., Ltd.
        • 9.4.3.1.1 Overview
        • 9.4.3.1.2 Top Product/Service Portfolio
        • 9.4.3.1.3 Top Competitors
        • 9.4.3.1.4 Key Personnel
        • 9.4.3.1.5 Analyst View
    • 9.4.4 Service Provider
      • 9.4.4.1 Natera, Inc.
        • 9.4.4.1.1 Overview
        • 9.4.4.1.2 Top Product/Service Portfolio
        • 9.4.4.1.3 Top Competitors
        • 9.4.4.1.4 Key Personnel
        • 9.4.4.1.5 Analyst View
      • 9.4.4.2 Myriad Genetics, Inc.
        • 9.4.4.2.1 Overview
        • 9.4.4.2.2 Top Product/Service Portfolio
        • 9.4.4.2.3 Top Competitors
        • 9.4.4.2.4 Key Personnel
        • 9.4.4.2.5 Analyst View
      • 9.4.4.3 Labcorp
        • 9.4.4.3.1 Overview
        • 9.4.4.3.2 Top Product/Service Portfolio
        • 9.4.4.3.3 Top Competitors
        • 9.4.4.3.4 Key Personnel
        • 9.4.4.3.5 Analyst View
      • 9.4.4.4 Quest Diagnostics Incorporated
        • 9.4.4.4.1 Overview
        • 9.4.4.4.2 Top Product/Service Portfolio
        • 9.4.4.4.3 Top Competitors
        • 9.4.4.4.4 Key Personnel
        • 9.4.4.4.5 Analyst View
      • 9.4.4.5 Vitrolife AB
        • 9.4.4.5.1 Overview
        • 9.4.4.5.2 Top Product/Service Portfolio
        • 9.4.4.5.3 Top Competitors
        • 9.4.4.5.4 Key Personnel
        • 9.4.4.5.5 Analyst View
      • 9.4.4.6 Fulgent Genetics
        • 9.4.4.6.1 Overview
        • 9.4.4.6.2 Top Product/Service Portfolio
        • 9.4.4.6.3 Top Competitors
        • 9.4.4.6.4 Key Personnel
        • 9.4.4.6.5 Analyst View
    • 9.4.5 List of Other Companies

10 Research Methodology

  • 10.1 Data Sources
    • 10.1.1 Primary Data Sources
    • 10.1.2 Secondary Data Sources
    • 10.1.3 Data Triangulation
  • 10.2 Market Estimation and Forecast

List of Figures

  • Figure 1: Global Genetic Screening and Testing for Reproductive Health Market (by Scenario), $Million, 2026, 2031, and 2036
  • Figure 2: Global Genetic Screening and Testing for Reproductive Health Market (by Region), $Million, 2025, 2031, 2036
  • Figure 3: Global Genetic Screening and Testing for Reproductive Health Market (by Offering), $Million, 2025, 2031, and 2036
  • Figure 4: Global Genetic Screening and Testing for Reproductive Health Market (by Test Type), $Million, 2025, 2031, and 2036
  • Figure 5: Global Genetic Screening and Testing for Reproductive Health Market (by Genetic Disorder), $Million, 2025, 2031, and 2036
  • Figure 6: Global Genetic Screening and Testing for Reproductive Health Market (Technology Approach, By Carrier Screening), $Million, 2025, 2031, and 2036
  • Figure 7: Global Genetic Screening and Testing for Reproductive Health Market (by Sample Type), $Million, 2025, 2031, and 2036
  • Figure 8: Global Genetic Screening and Testing for Reproductive Health Market (by End User), $Million, 2025, 2031, and 2036
  • Figure 9: Reproductive Genetic Screening and Testing Workflow
  • Figure 10: Global Genetic Screening and Testing for Reproductive Health Market (by Offering), $Million, 2025, 2031, and 2036
  • Figure 11: Global Genetic Screening and Testing for Reproductive Health Market (Product), $Million, 2024-2036
  • Figure 12: Global Genetic Screening and Testing for Reproductive Health Market (Consumables and Reagents), $Million, 2024-2036
  • Figure 13: Global Genetic Screening and Testing for Reproductive Health Market (NGS-Based Consumables and Reagents), $Million, 2024-2036
  • Figure 14: Global Genetic Screening and Testing for Reproductive Health Market (Microarray-Based Consumables and Reagents), $Million, 2024-2036
  • Figure 15: Global Genetic Screening and Testing for Reproductive Health Market (Other Consumables and Reagents), $Million, 2024-2036
  • Figure 16: Global Genetic Screening and Testing for Reproductive Health Market (Instruments), $Million, 2024-2036
  • Figure 17: Global Genetic Screening and Testing for Reproductive Health Market (Software and Bioinformatics), $Million, 2024-2036
  • Figure 18: Global Genetic Screening and Testing for Reproductive Health Market (Services), $Million, 2024-2036
  • Figure 19: Global Genetic Screening and Testing for Reproductive Health Market (by Test Type), $Million, 2025, 2031, and 2036
  • Figure 20: Global Genetic Screening and Testing for Reproductive Health Market (Carrier Screening), $Million, 2024-2036
  • Figure 21: Global Genetic Screening and Testing for Reproductive Health Market (Expanded Carrier Screening), $Million, 2024-2036
  • Figure 22: Global Genetic Screening and Testing for Reproductive Health Market (Targeted Carrier Screening ), $Million, 2024-2036
  • Figure 23: Global Genetic Screening and Testing for Reproductive Health Market (Infertility Genetic Testing), $Million, 2024-2036
  • Figure 24: Global Genetic Screening and Testing for Reproductive Health Market (Preimplantation Genetic Testing (PGT)), $Million, 2024-2036
  • Figure 25: Global Genetic Screening and Testing for Reproductive Health Market (Preimplantation Genetic Testing for Aneuploidy (PGT-A)), $Million, 2024-2036
  • Figure 26: Global Genetic Screening and Testing for Reproductive Health Market (Preimplantation Genetic Testing for Structural Rearrangements (PGT-SR)), $Million, 2024-2036
  • Figure 27: Global Genetic Screening and Testing for Reproductive Health Market (Preimplantation Genetic Testing for Monogenic Disorders (PGT-M)), $Million, 2024-2036
  • Figure 28: Global Genetic Screening and Testing for Reproductive Health Market (Preimplantation Genetic Testing for Polygenic Disorders (PGT-P)), $Million, 2024-2036
  • Figure 29: Global Genetic Screening and Testing for Reproductive Health Market (Non-Invasive Prenatal Testing), $Million, 2024-2036
  • Figure 30: Global Genetic Screening and Testing for Reproductive Health Market (Others), $Million, 2024-2036
  • Figure 31: Global Genetic Screening and Testing for Reproductive Health Market (by Genetic Disorder), $Million, 2025, 2031, and 2036
  • Figure 32: Global Genetic Screening and Testing for Reproductive Health Market, Genetic Disorder, (Chromosomal Abnormalities), $Million, 2024-2036
  • Figure 33: Global Genetic Screening and Testing for Reproductive Health Market, Chromosomal Abnormalities, (Aneuploidies), $Million, 2024-2036
  • Figure 34: Global Genetic Screening and Testing for Reproductive Health Market, Chromosomal Abnormalities, (Structural Chromosomal Abnormalities), $Million, 2024-2036
  • Figure 35: Global Genetic Screening and Testing for Reproductive Health Market, Chromosomal Abnormalities, (Copy Number Variations/Microdeletions and Microduplications), $Million, 2024-2036
  • Figure 36: Global Genetic Screening and Testing for Reproductive Health Market, Genetic Disorder, (Single-Gene/Monogenic Genetic Disorders), $Million, 2024-2036
  • Figure 37: Global Genetic Screening and Testing for Reproductive Health Market, Single-Gene/Monogenic Genetic Disorders, (Autosomal Recessive Genetic Disorders), $Million, 2024-2036
  • Figure 38: Global Genetic Screening and Testing for Reproductive Health Market, Single-Gene/Monogenic Genetic Disorders, (Autosomal Dominant Genetic Disorders), $Million, 2024-2036
  • Figure 39: Global Genetic Screening and Testing for Reproductive Health Market, Single-Gene/Monogenic Genetic Disorders, (X-Linked Genetic Disorders), $Million, 2024-2036
  • Figure 40: Global Genetic Screening and Testing for Reproductive Health Market, (Others), $Million, 2024-2036
  • Figure 41: Global Genetic Screening and Testing for Reproductive Health Market (by Technology Approach), $Million, 2025, 2031, and 2036
  • Figure 42: Global Genetic Screening and Testing for Reproductive Health Market, Technology Approach (Carrier Screening), $Million, 2024-2036
  • Figure 43: Global Genetic Screening and Testing for Reproductive Health Market (Targeted NGS Panel-Based Carrier Screening), $Million, 2024-2036
  • Figure 44: Global Genetic Screening and Testing for Reproductive Health Market (Whole-Exome Sequencing-Based Carrier Screening), $Million, 2024-2036
  • Figure 45: Global Genetic Screening and Testing for Reproductive Health Market (Whole-Genome Sequencing-Based Carrier Screening), $Million, 2024-2036
  • Figure 46: Global Genetic Screening and Testing for Reproductive Health Market (Microarray/SNP Genotyping-Based Carrier Screening), $Million, 2024-2036
  • Figure 47: Global Genetic Screening and Testing for Reproductive Health Market (Others), $Million, 2024-2036
  • Figure 48: Global Genetic Screening and Testing for Reproductive Health Market, Technology Approach (Infertility Genetic Testing), $Million, 2024-2036
  • Figure 49: Global Genetic Screening and Testing for Reproductive Health Market (Cytogenetic Testing), $Million, 2024-2036
  • Figure 50: Global Genetic Screening and Testing for Reproductive Health Market (Microarray/SNP Array-Based Testing), $Million, 2024-2036
  • Figure 51: Global Genetic Screening and Testing for Reproductive Health Market (NGS Panel-Based Testing), $Million, 2024-2036
  • Figure 52: Global Genetic Screening and Testing for Reproductive Health Market (Others), $Million, 2024-2036
  • Figure 53: Global Genetic Screening and Testing for Reproductive Health Market, Technology Approach (Preimplantation Genetic Testing (PGT)), $Million, 2024-2036
  • Figure 54: Global Genetic Screening and Testing for Reproductive Health Market (Whole-Genome Sequencing-Based PGT), $Million, 2024-2036
  • Figure 55: Global Genetic Screening and Testing for Reproductive Health Market (Targeted NGS-Based PGT), $Million, 2024-2036
  • Figure 56: Global Genetic Screening and Testing for Reproductive Health Market (Others), $Million, 2024-2036
  • Figure 57: Global Genetic Screening and Testing for Reproductive Health Market, Technology Approach (Non-Invasive Prenatal Testing), $Million, 2024-2036
  • Figure 58: Global Genetic Screening and Testing for Reproductive Health Market (Whole-Genome Sequencing/Massively Parallel Shotgun Sequencing-Based NIPT), $Million, 2024-2036
  • Figure 59: Global Genetic Screening and Testing for Reproductive Health Market (Targeted Approach-Based NIPT), $Million, 2024-2036
  • Figure 60: Global Genetic Screening and Testing for Reproductive Health Market (SNP Analysis), $Million, 2024-2036
  • Figure 61: Global Genetic Screening and Testing for Reproductive Health Market (Microarray Analysis), $Million, 2024-2036
  • Figure 62: Global Genetic Screening and Testing for Reproductive Health Market (Rolling Circle Amplification-Based NIPT), $Million, 2024-2036
  • Figure 63: Global Genetic Screening and Testing for Reproductive Health Market, Non-Invasive Prenatal Testing (Others), $Million, 2024-2036
  • Figure 64: Global Genetic Screening and Testing for Reproductive Health Market, Technology Approach (Others), $Million, 2024-2036
  • Figure 65: Global Genetic Screening and Testing for Reproductive Health Market, Others (NGS-Based Testing), $Million, 2024-2036
  • Figure 66: Global Genetic Screening and Testing for Reproductive Health Market, Others (Microarray-Based Testing), $Million, 2024-2036
  • Figure 67: Global Genetic Screening and Testing for Reproductive Health Market, Others (Other Approaches), $Million, 2024-2036
  • Figure 68: Global Genetic Screening and Testing for Reproductive Health Market (by Sample Type), $Million, 2025, 2031, and 2036
  • Figure 69: Global Genetic Screening and Testing for Reproductive Health Market (Blood), $Million, 2024-2036
  • Figure 70: Global Genetic Screening and Testing for Reproductive Health Market (Saliva), $Million, 2024-2036
  • Figure 71: Global Genetic Screening and Testing for Reproductive Health Market (Buccal Swab), $Million, 2024-2036
  • Figure 72: Global Genetic Screening and Testing for Reproductive Health Market (Embryonic Cells), $Million, 2024-2036
  • Figure 73: Global Genetic Screening and Testing for Reproductive Health Market (Amniotic Fluid), $Million, 2024-2036
  • Figure 74: Global Genetic Screening and Testing for Reproductive Health Market (Fetal and Placental Tissue), $Million, 2024-2036
  • Figure 75: Global Genetic Screening and Testing for Reproductive Health Market (Others), $Million, 2024-2036
  • Figure 76: Global Genetic Screening and Testing for Reproductive Health Market (by End User), $Million, 2025, 2031, and 2036
  • Figure 77: Global Genetic Screening and Testing for Reproductive Health Market (Hospitals), $Million, 2024-2036
  • Figure 78: Global Genetic Screening and Testing for Reproductive Health Market (Fertility and IVF Clinics), $Million, 2024-2036
  • Figure 79: Global Genetic Screening and Testing for Reproductive Health Market (Diagnostic, Reference, and Genetic Testing Laboratories), $Million, 2024-2036
  • Figure 80: Global Genetic Screening and Testing for Reproductive Health Market (Others), $Million, 2024-2036
  • Figure 81: North America Genetic Screening and Testing for Reproductive Health Market, $Million, 2024-2036
  • Figure 82: U.S. Genetic Screening and Testing for Reproductive Health Market, $Million, 2024-2036
  • Figure 83: Canada Genetic Screening and Testing for Reproductive Health Market, $Million, 2024-2036
  • Figure 84: Europe, Middle East and Africa Genetic Screening and Testing for Reproductive Health Market, $Million, 2024-2036
  • Figure 85: Western Europe Genetic Screening and Testing for Reproductive Health Market, $Million, 2024-2036
  • Figure 86: Commonwealth of Independent States (CIS) Genetic Screening and Testing for Reproductive Health Market, $Million, 2024-2036
  • Figure 87: Nordics and South-Eastern/Central Eastern Europe (NSSE) Genetic Screening and Testing for Reproductive Health Market, $Million, 2024-2036
  • Figure 88: Middle East Genetic Screening and Testing for Reproductive Health Market, $Million, 2024-2036
  • Figure 89: Africa Genetic Screening and Testing for Reproductive Health Market, $Million, 2024-2036
  • Figure 90: Asia-Pacific Genetic Screening and Testing for Reproductive Health Market, $Million, 2024-2036
  • Figure 91: China Genetic Screening and Testing for Reproductive Health Market, $Million, 2024-2036
  • Figure 92: India Genetic Screening and Testing for Reproductive Health Market, $Million, 2024-2036
  • Figure 93: Japan Genetic Screening and Testing for Reproductive Health Market, $Million, 2024-2036
  • Figure 94: South Korea Genetic Screening and Testing for Reproductive Health Market, $Million, 2024-2036
  • Figure 95: Australia Genetic Screening and Testing for Reproductive Health Market, $Million, 2024-2036
  • Figure 96: Taiwan Genetic Screening and Testing for Reproductive Health Market, $Million, 2024-2036
  • Figure 97: Thailand Genetic Screening and Testing for Reproductive Health Market, $Million, 2024-2036
  • Figure 98: Vietnam Genetic Screening and Testing for Reproductive Health Market, $Million, 2024-2036
  • Figure 99: Malaysia Genetic Screening and Testing for Reproductive Health Market, $Million, 2024-2036
  • Figure 100: Rest-of-Asia-Pacific Genetic Screening and Testing for Reproductive Health Market, $Million, 2024-2036
  • Figure 101: Latin America Genetic Screening and Testing for Reproductive Health Market, $Million, 2024-2036
  • Figure 102: Brazil Genetic Screening and Testing for Reproductive Health Market, $Million, 2024-2036
  • Figure 103: Mexico Genetic Screening and Testing for Reproductive Health Market, $Million, 2024-2036
  • Figure 104: Argentina Genetic Screening and Testing for Reproductive Health Market, $Million, 2024-2036
  • Figure 105: Colombia Genetic Screening and Testing for Reproductive Health Market, $Million, 2024-2036
  • Figure 106: Chile Genetic Screening and Testing for Reproductive Health Market, $Million, 2024-2036
  • Figure 107: Peru Genetic Screening and Testing for Reproductive Health Market, $Million, 2024-2036
  • Figure 108: Costa Rica Genetic Screening and Testing for Reproductive Health Market, $Million, 2024-2036
  • Figure 109: Ecuador Genetic Screening and Testing for Reproductive Health Market, $Million, 2024-2036
  • Figure 110: Panama Genetic Screening and Testing for Reproductive Health Market, $Million, 2024-2036
  • Figure 111: Puerto Rico Genetic Screening and Testing for Reproductive Health Market, $Million, 2024-2036
  • Figure 112: Dominican Republic Genetic Screening and Testing for Reproductive Health Market, $Million, 2024-2036
  • Figure 113: Rest-of-Latin America Genetic Screening and Testing for Reproductive Health Market, $Million, 2024-2036
  • Figure 114: Global Genetic Screening and Testing for Reproductive Health Market, Company Share Analysis, Product, 2025
  • Figure 115: Global Genetic Screening and Testing for Reproductive Health Market, Company Share Analysis, Services, 2025
  • Figure 116: Data Triangulation
  • Figure 117: Top-Down and Bottom-Up Approach
  • Figure 118: Assumptions and Limitations

List of Tables

  • Table 1: Market Snapshot
  • Table 2: Reproductive Genetic Screening and Testing Initiatives (by Geography)
  • Table 3: Pricing Analysis of Selected Products in the Global Genetic Screening and Testing for Reproductive Health Market (by Product Company)
  • Table 4: Pricing Analysis of Selected Products in the Global Genetic Screening and Testing for Reproductive Health Market (by Test Provider)
  • Table 5: Drivers, Challenges, and Opportunities: Current and Future Impact Assessment
  • Table 6: Global Genetic Screening and Testing for Reproductive Health Market (by Region), $Million, 2024-2036
  • Table 7: North America Genetic Screening and Testing for Reproductive Health Market (by Country), $Million, 2024-2036
  • Table 8: North America Genetic Screening and Testing for Reproductive Health Market, Testing Volume, 2024-2036, Thousand
  • Table 9: North America Genetic Screening and Testing for Reproductive Health Market, Testing Volume, by Preimplantation Genetic Testing (PGT), 2024-2036, Thousand
  • Table 10: North America Genetic Screening and Testing for Reproductive Health Market, Testing Volume, by PGT-A Biopsy Samples Tested,2024-2036, Thousand
  • Table 11: North America Genetic Screening and Testing for Reproductive Health Market (by Offering), $Million, 2024-2036
  • Table 12: North America Genetic Screening and Testing for Reproductive Health Market (by Products), $Million, 2024-2036
  • Table 13: North America Genetic Screening and Testing for Reproductive Health Market (by Test Type), $Million, 2024-2036
  • Table 14: North America Genetic Screening and Testing for Reproductive Health Market, Test Type, (by Carrier Screening), $Million, 2024-2036
  • Table 15: North America Genetic Screening and Testing for Reproductive Health Market, Test Type, (by Preimplantation Genetic Testing (PGT)), $Million, 2024-2036
  • Table 16: North America Genetic Screening and Testing for Reproductive Health Market, By Technology Approach, $Million, 2024-2036
  • Table 17: North America Genetic Screening and Testing for Reproductive Health Market, Technology Approach, By Carrier Screening, $Million, 2024-2036
  • Table 18: North America Genetic Screening and Testing for Reproductive Health Market, Technology Approach, By Infertility Genetic Testing, $Million, 2024-2036
  • Table 19: North America Genetic Screening and Testing for Reproductive Health Market, Technology Approach, By Preimplantation Genetic Testing (PGT), $Million, 2024-2036
  • Table 20: North America Genetic Screening and Testing for Reproductive Health Market, Technology Approach, By Non-Invasive Prenatal Testing, $Million, 2024-2036
  • Table 21: North America Genetic Screening and Testing for Reproductive Health Market, Technology Approach, By Others, $Million, 2024-2036
  • Table 22: Europe, Middle East and Africa Genetic Screening and Testing for Reproductive Health Market (by Country), $Million, 2024-2036
  • Table 23: Europe, Middle East and Africa Genetic Screening and Testing for Reproductive Health Market, Testing Volume, 2024-2036, Thousand
  • Table 24: Europe, Middle East and Africa Genetic Screening and Testing for Reproductive Health Market, Testing Volume, by Preimplantation Genetic Testing (PGT), 2024-2036, Thousand
  • Table 25: Europe, Middle East and Africa Genetic Screening and Testing for Reproductive Health Market, Testing Volume, by PGT-A Biopsy Samples Tested,2024-2036, Thousand
  • Table 26: Europe, Middle East and Africa Genetic Screening and Testing for Reproductive Health Market (by Offering), $Million, 2024-2036
  • Table 27: Europe, Middle East and Africa Genetic Screening and Testing for Reproductive Health Market (by Products), $Million, 2024-2036
  • Table 28: Europe, Middle East and Africa Genetic Screening and Testing for Reproductive Health Market (by Test Type), $Million, 2024-2036
  • Table 29: Europe, Middle East and Africa Genetic Screening and Testing for Reproductive Health Market, Test Type, (by Carrier Screening), $Million, 2024-2036
  • Table 30: Europe, Middle East and Africa Genetic Screening and Testing for Reproductive Health Market, Test Type, (by Preimplantation Genetic Testing (PGT)), $Million, 2024-2036
  • Table 31: Europe, Middle East and Africa Genetic Screening and Testing for Reproductive Health Market, By Technology Approach, $Million, 2024-2036
  • Table 32: Europe, Middle East and Africa Genetic Screening and Testing for Reproductive Health Market, Technology Approach, By Carrier Screening, $Million, 2024-2036
  • Table 33: Europe, Middle East and Africa Genetic Screening and Testing for Reproductive Health Market, Technology Approach, By Infertility Genetic Testing, $Million, 2024-2036
  • Table 34: Europe, Middle East and Africa Genetic Screening and Testing for Reproductive Health Market, Technology Approach, By Preimplantation Genetic Testing (PGT), $Million, 2024-2036
  • Table 35: Europe, Middle East and Africa Genetic Screening and Testing for Reproductive Health Market, Technology Approach, By Non-Invasive Prenatal Testing, $Million, 2024-2036
  • Table 36: Europe, Middle East and Africa Genetic Screening and Testing for Reproductive Health Market, Technology Approach, By Others, $Million, 2024-2036
  • Table 37: Asia-Pacific Genetic Screening and Testing for Reproductive Health Market (by Country), $Million, 2024-2036
  • Table 38: Asia-Pacific Genetic Screening and Testing for Reproductive Health Market, Testing Volume, 2024-2036, Thousand
  • Table 39: Asia-Pacific Genetic Screening and Testing for Reproductive Health Market, Testing Volume, by Preimplantation Genetic Testing (PGT), 2024-2036, Thousand
  • Table 40: Asia-Pacific Genetic Screening and Testing for Reproductive Health Market, Testing Volume, by PGT-A Biopsy Samples Tested,2024-2036, Thousand
  • Table 41: Asia-Pacific Genetic Screening and Testing for Reproductive Health Market (by Offering), $Million, 2024-2036
  • Table 42: Asia-Pacific Genetic Screening and Testing for Reproductive Health Market (by Products), $Million, 2024-2036
  • Table 43: Asia-Pacific Genetic Screening and Testing for Reproductive Health Market (by Test Type), $Million, 2024-2036
  • Table 44: Asia-Pacific Genetic Screening and Testing for Reproductive Health Market, Test Type, (by Carrier Screening), $Million, 2024-2036
  • Table 45: Asia-Pacific Genetic Screening and Testing for Reproductive Health Market, Test Type, (by Preimplantation Genetic Testing (PGT)), $Million, 2024-2036
  • Table 46: Asia-Pacific Genetic Screening and Testing for Reproductive Health Market, By Technology Approach, $Million, 2024-2036
  • Table 47: Asia-Pacific Genetic Screening and Testing for Reproductive Health Market, Technology Approach, By Carrier Screening, $Million, 2024-2036
  • Table 48: Asia-Pacific Genetic Screening and Testing for Reproductive Health Market, Technology Approach, By Infertility Genetic Testing, $Million, 2024-2036
  • Table 49: Asia-Pacific Genetic Screening and Testing for Reproductive Health Market, Technology Approach, By Preimplantation Genetic Testing (PGT), $Million, 2024-2036
  • Table 50: Asia-Pacific Genetic Screening and Testing for Reproductive Health Market, Technology Approach, By Non-Invasive Prenatal Testing, $Million, 2024-2036
  • Table 51: Asia-Pacific Genetic Screening and Testing for Reproductive Health Market, Technology Approach, By Others, $Million, 2024-2036
  • Table 52: Latin America Genetic Screening and Testing for Reproductive Health Market (by Country), $Million, 2024-2036
  • Table 53: Latin America Genetic Screening and Testing for Reproductive Health Market, Testing Volume, 2024-2036, Thousand
  • Table 54: Latin America Genetic Screening and Testing for Reproductive Health Market, Testing Volume, by Preimplantation Genetic Testing (PGT), 2024-2036, Thousand
  • Table 55: Latin America Genetic Screening and Testing for Reproductive Health Market, Testing Volume, by PGT-A Biopsy Samples Tested,2024-2036, Thousand
  • Table 56: Latin America Genetic Screening and Testing for Reproductive Health Market (by Offering), $Million, 2024-2036
  • Table 57: Latin America Genetic Screening and Testing for Reproductive Health Market (by Products), $Million, 2024-2036
  • Table 58: Latin America Genetic Screening and Testing for Reproductive Health Market (by Test Type), $Million, 2024-2036
  • Table 59: Latin America Genetic Screening and Testing for Reproductive Health Market, Test Type, (by Carrier Screening), $Million, 2024-2036
  • Table 60: Latin America Genetic Screening and Testing for Reproductive Health Market, Test Type, (by Preimplantation Genetic Testing (PGT)), $Million, 2024-2036
  • Table 61: Latin America Genetic Screening and Testing for Reproductive Health Market, By Technology Approach, $Million, 2024-2036
  • Table 62: Latin America Genetic Screening and Testing for Reproductive Health Market, Technology Approach, By Carrier Screening, $Million, 2024-2036
  • Table 63: Latin America Genetic Screening and Testing for Reproductive Health Market, Technology Approach, By Infertility Genetic Testing, $Million, 2024-2036
  • Table 64: Latin America Genetic Screening and Testing for Reproductive Health Market, Technology Approach, By Preimplantation Genetic Testing (PGT), $Million, 2024-2036
  • Table 65: Latin America Genetic Screening and Testing for Reproductive Health Market, Technology Approach, By Non-Invasive Prenatal Testing, $Million, 2024-2036
  • Table 66: Latin America Genetic Screening and Testing for Reproductive Health Market, Technology Approach, By Others, $Million, 2024-2036
  • Table 67: Product Benchmarking by Offering
  • Table 68: Product Benchmarking by Offering
  • Table 69: Some of the Major Key Strategies, March 2025-July 2026